Track market-moving stories before they get noisy

Greystone Logistics (OTCMKTS:GLGI – Get Free Report) and Energizer (NYSE:ENR – Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation This table compares Greystone Logistics and Energizer”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greystone Logistics $57.87 million 0.13 $2.35 million ($0.04) -7.00 Energizer $2.95 billion 0.38 $239.00 million $2.97 5.53 Energizer has higher revenue and earnings than Greystone Logistics. Greystone Logistics is trading at a lower price-to-earnings ratio than Energizer, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk Greystone Logistics has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Energizer has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Analyst Recommendations This is a breakdown of current recommendations for Greystone Logistics and Energizer, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greystone Logistics 0 0 0 0 0.00 Energizer 0 7 1 0 2.13 Energizer has a consensus target price of $25.29, suggesting a potential upside of 53.94%. Given Energizer’s stronger consensus rating and higher probable upside, analysts clearly believe Energizer is more favorable than Greystone Logistics.

Insider and Institutional Ownership 10.3% of Greystone Logistics shares are owned by institutional investors. Comparatively, 93.7% of Energizer shares are owned by institutional investors. 1.6% of Energizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability This table compares Greystone Logistics and Energizer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Greystone Logistics -1.86% -4.88% -2.10% Energizer 7.11% 143.24% 5.08% Summary Energizer beats Greystone Logistics on 14 of the 14 factors compared between the two stocks.

About Greystone Logistics (Get Free Report)

Greystone Logistics, Inc., through its subsidiaries, manufactures and markets plastic pallets and pelletized recycled plastic resins in the United States. The company offers rackable, can, nestable, display, monoblock, half-barrel and slim keg stackable, drum, and mid duty pallets. It sells its pallets directly, as well as through a network of independent contractor distributors. The company was formerly known as PalWeb Corporation and changed its name to Greystone Logistics, Inc. in March 2005. Greystone Logistics, Inc. was incorporated in 1969 and is based in Tulsa, Oklahoma.

About Energizer (Get Free Report)

Energizer Holdings, Inc., together with its subsidiaries, manufactures, markets, and distributes household batteries, specialty batteries, and lighting products worldwide. It offers lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide batteries under the Energizer, Eveready, and Rayovac brands; primary, rechargeable, specialty, and hearing aid batteries; and handheld, headlights, lanterns, and area lights, as well as flashlights under the Hard Case, Dolphin, and WeatherReady brands. The company licenses the Energizer, Rayovac, and Eveready brands to companies developing consumer solutions in solar, automotive batteries, portable power for critical devices, generators, power tools, household light bulbs, and other lighting products. In addition, it designs and markets automotive fragrance and appearance products, including protectants, wipes, tire and wheel care products, glass cleaners, leather care products, air fresheners, and washes to clean, shine, refresh, and protect interior and exterior automobile surfaces under the brand names of Armor All, Nu Finish, Refresh Your Car!, LEXOL, Eagle One, California Scents, Driven, Bahama & Co, Carnu, Grand Prix, Kit, and Tempo; STP branded fuel and oil additives, functional fluids, and other performance chemical products; and do-it-yourself automotive air conditioning recharge products under the A/C PRO brand name, as well as other refrigerant and recharge kits, sealants, and accessories. The company sells its products through direct sales force, distributors, and wholesalers; and various retail and business-to-business channels, including mass merchandisers, club, electronics, food, home improvement, dollar store, auto, drug, hardware, e-commerce, convenience, sporting goods, hobby/craft, office, industrial, medical, and catalog. Energizer Holdings, Inc. was incorporated in 2015 and is headquartered in Saint Louis, Missouri.

Receive News & Ratings for Greystone Logistics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greystone Logistics and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Energizer Holdings, Inc. (NYSE: ENR) will report its Second Quarter Fiscal Year 2026 results before the market opens on May 5. Energizer also will discuss its results during an investor conference call that will be webcast beginning at 10 a.m. ET. The call will be hosted by Mark LaVigne, Chief Executive Officer, and John Drabik, Chief Financial Officer.

Interested parties can access the live webcast, earnings press release, management prepared remarks, and related earnings presentation at www.energizerholdings.com, under the Investors and Events & Presentations tabs. The earnings press release, management prepared remarks, and related earnings presentation will be available prior to market open on May 5. The webcast can also be accessed directly via the following link:

https://app.webinar.net/zVbKaYVGy8D

For those unable to participate during the live webcast, a replay will be available at www.energizerholdings.com, under the Investors, Events & Presentations and Quarterly Results tabs.

About Energizer:

Energizer Holdings ("Energizer,"NYSE: ENR), headquartered in St. Louis, is one of the world's largest manufacturers and distributors of primary batteries, portable lights, and auto care appearance, performance, refrigerant, and fragrance products. Our portfolio of globally recognized brands include Energizer, Eveready Armor All, Rayovac, STP, A/C Pro, Refresh Your Car!, California Scents, Driven, Bahama & Co., LEXOL, Eagle One, NEVR-DULL, Nu Finish, Son of a Gun, Scratch Doctor, Tuff Stuff, Carnu, Grand Prix, Kit, Tempo and Centralsul. As a global branded consumer products company, Energizer's mission is to be the leader in our categories by better serving consumers and customers. Visit www.energizerholdings.com for more details.

SOURCE Energizer Holdings, Inc.

Energizer Holdings offers a compelling 6% dividend yield, but faces high leverage and stagnant growth prospects. ENR's net leverage stands at 5x, with limited organic growth and a dilutive auto care segment weighing on margins and strategy. Dividend coverage is currently sufficient, supported by improved free cash flow, though sustainability hinges on execution and potential strategic actions.

BBB Foods (TBBB - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 6. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis discount retailer is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of -375%.

Revenues are expected to be $1.28 billion, up 52.9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 36.36% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for BBB Foods?For BBB Foods, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -26.32%.

On the other hand, the stock currently carries a Zacks Rank of #5.

So, this combination makes it difficult to conclusively predict that BBB Foods will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that BBB Foods would post a loss of$0.28 per share when it actually produced a loss of -$0.49, delivering a surprise of -75.00%.

The company has not been able to beat consensus EPS estimates in any of the last four quarters.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

BBB Foods doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Consumer Products - Staples industry, Energizer Holdings (ENR - Free Report) , is soon expected to post earnings of $0.47 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of -29.9%. Revenues for the quarter are expected to be $665.21 million, up 0.4% from the year-ago quarter.

The consensus EPS estimate for Energizer has been revised 0.7% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +1.41%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Energizer will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Second Quarter Highlights

Net sales of $643.3 million, -3.0% to prior year Gross Margin of 40.2% and 44.4% on an adjusted basis, inclusive of a $47.6 million tariff refund benefit(1) Earnings per share of $0.15 & Adjusted Earnings per share of $0.94(1) Updating fiscal year outlook to low single digit Net sales growth, roughly flat organic Net sales and Adjusted Earnings per share and Adjusted EBITDA to the high end of our previously provided ranges , /PRNewswire/ -- Energizer Holdings, Inc. (NYSE: ENR) today announced results for the second fiscal quarter ended March 31, 2026.  

"Our strategic priorities in Fiscal 2026 remain clear: restoring growth, rebuilding margins impacted by tariffs, and returning the business to its long‑term historical cash flow profile," said Mark LaVigne, Chief Executive Officer. "During the second quarter, we continued to make meaningful progress against these priorities, highlighted by significant gross margin recovery and growing confidence in a return to organic growth in the back half of the year.  Our disciplined execution is translating into tangible improvements across the income statement, strengthening our confidence in delivering the high end of our full year earnings outlook."

Top-Line Performance

For the quarter, we had Net sales of $643.3 million compared to $662.9 million in the prior year period.

Second Quarter

% Chg

Net sales - FY'25

$                662.9

Organic

(36.6)

(5.5) %

Acquisition impact

2.1

0.3 %

Change in highly inflationary markets

(1.1)

(0.2) %

Impact of currency

16.0

2.4 %

Net sales - FY'26

$                643.3

(3.0) %

Organic Net sales decreased 5.5% primarily due to the following items:

A shift in the timing of battery orders related to the plastic free conversion, a slower start to the selling season in auto care and a modest impact from the conflict in the Middle East resulted in volume declines of 6.1%. Carry over price increases of 0.6%, primarily in the Batteries & Lights segment, partially  offset the volume declines. The Advanced Power Solutions (APS) acquisition completed on May 2, 2025 contributed $2.1 million to Net sales during the quarter ended March 31, 2026.

Gross Margin

Gross margin percentage on a reported basis was 40.2% versus 39.1% in the prior year. Excluding restructuring and related costs in the current and prior year of $27.1 million and $8.7 million, respectively, and the prior year network transition costs of $2.7 million, Adjusted Gross margin was 44.4% compared to 40.8% in the prior year, an increase of 360 basis points.(1)

Second Quarter

Gross margin - FY'25 Reported

39.1 %

Prior year impact of restructuring and related costs and network transition costs

1.7 %

Gross margin - FY'25 Adjusted(1)

40.8 %

Net tariff impact - inclusive of refund benefit

4.8 %

FY26 production credits

1.8 %

Pricing

0.3 %

Product mix

(2.4) %

Product cost impacts

(1.0) %

All other, including currency impacts

0.1 %

Gross margin - FY'26 Adjusted(1)

44.4 %

Current year impact of restructuring and related costs

(4.2) %

Gross margin - FY'26 Reported

40.2 %

Gross margin and Adjusted Gross margin improvement was driven by a benefit of $47.6 million related to the anticipated refund related to tariffs previously enacted under the International Emergency Powers Act (IEEPA), as well as production tax credits of $11.7 million and benefits from price increases. The improvements were partially offset by increased input costs from production inefficiencies associated with rebalancing our network, other incremental tariffs incurred in the quarter and unfavorable product mix.(1)

Selling, General and Administrative Expense (SG&A)

SG&A, excluding restructuring and acquisition costs, was 19.8% of Net sales for the second quarter, or $127.1 million, compared to 18.8%, or $124.5 million in the prior year. The year-over-year dollar increase was primarily driven by increased SG&A from the APS business of $3.0 million, investment in digital transformation and growth initiatives and unfavorable currency. The increase was partially offset by Project Momentum savings of approximately $4 million in the quarter.(1)

Advertising and Promotion Expense (A&P)

A&P expense decreased $1.8 million for the second fiscal quarter to 3.0% of Net sales, compared to 3.1% in the prior year.

Earnings Per Share and Adjusted EBITDA

Second Quarter

(In millions, except per share data)

2026

2025

Net earnings

$      10.1

$      28.3

Diluted net earnings per common share

$      0.15

$      0.39

Adjusted Net earnings(1)

$      65.1

$      49.4

Adjusted Diluted net earnings per common share(1)

$      0.94

$      0.67

Adjusted EBITDA(1)

$     158.6

$     140.3

Currency neutral Adjusted Diluted net earnings per common share(1)

$      0.89

Currency neutral Adjusted EBITDA(1)

$     154.7

Net earnings, Earnings per share, Adjusted Earnings per share and Adjusted EBITDA were impacted by the benefit of the tariff refund recorded in Gross margin and lower A&P and R&D spend.  These benefits were partially offset by the decline in Net sales and an increase in SG&A driven by the APS acquisition.  Adjusted Net earnings and Adjusted Earnings per share were further impacted by increased interest expense due to a higher average debt balance in the current year quarter.

Net earnings and Earning per share were also impacted by the non-cash settlement charge of $26.1 million recorded in the quarter related to the settlement loss on the termination of the U.K. pension plan.

Free cash flow and Capital allocation

Operating cash flow for the six months ended March 31, 2026 was $147.8 million, and Free cash flow was $105.9 million, or 7.4% of Net sales. Dividend payments in the quarter were $20.6 million, or $0.30 per common share. Financial Outlook and Assumptions for Fiscal Year 2026(1)

For fiscal 2026, we expect Net sales to be up low single digits and organic Net sales to be roughly flat. Adjusted Gross margin is now expected to be between 40% and 41%, primarily due to the benefit of the tariff refund. As a result, we expect to deliver Adjusted Earnings per share for the full year at the high end of the previously provided range of $3.30 to $3.60 and Adjusted EBITDA at the high end of the previously provided range of $580 to $610 million. 

For the third fiscal quarter, we anticipate low single digit organic Net sales growth and expect to deliver Adjusted Earnings per share in the range of $0.75 to $0.85. 

Webcast Information

In conjunction with this announcement, the Company will post prepared comments under the Investor/Events & Presentations section of the Company website around 7:00 a.m. Eastern Time today and will hold an investor conference call beginning at 10:00 a.m. Eastern Time today. The call will focus on second fiscal quarter earnings and recent trends in the business. All interested parties may access a live webcast of this conference call at www.energizerholdings.com, under "Investors" and "Events and Presentations" tabs or by using the following link:

https://app.webinar.net/zVbKaYVGy8D

For those unable to participate during the live webcast, a replay will be available on www.energizerholdings.com, under "Investors," "Events and Presentations," and "Past Events" tabs.

This document contains both historical and forward-looking statements. Forward-looking statements are not based on historical facts but instead reflect our expectations, estimates or projections concerning future results or events, including, without limitation, the future sales, gross margins, costs, earnings, cash flows, tax rates and performance of the Company. These statements generally can be identified by the use of forward-looking words or phrases such as "believe," "expect," "expectation," "anticipate," "may," "could," "will," "intend," "belief," "estimate," "plan," "target," "predict," "likely," "should," "forecast," "outlook," or other similar words or phrases. These statements are not guarantees of performance and are inherently subject to known and unknown risks, uncertainties and assumptions that are difficult to predict and could cause our actual results to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or projections will be achieved. The forward-looking statements included in this document are only made as of the date of this document and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Numerous factors could cause our actual results and events to differ materially from those expressed or implied by forward-looking statements, including, without limitation:

Global economic and financial market conditions beyond our control might materially and negatively impact us. Competition in our product categories might hinder our ability to execute our business strategy, achieve profitability, or maintain relationships with existing customers. Changes in the retail environment and consumer preferences could adversely affect our business, financial condition and results of operations. Loss or impairment of the reputation of our Company or our leading brands or failure of our marketing plans could have an adverse effect on our business. Loss of any of our principal customers could significantly decrease our sales and profitability. Our ability to meet our growth targets depends on successful product, marketing and operations innovation and successful responses to competitive innovation and changing consumer habits. We are subject to risks related to our international operations, including tariff and currency fluctuations, which could adversely affect our results of operations. We must successfully manage the demand, supply, and operational challenges brought on by any disease outbreak, including epidemics, pandemics, or similar widespread public health concerns. If we fail to protect our intellectual property rights, competitors may manufacture and market similar products, which could adversely affect our market share and results of operations. Changes in production costs, including raw material prices and transportation costs, from tariffs, inflation or otherwise, have adversely affected, and in the future could erode, our profit margins and negatively impact operating results. Our reliance on certain significant suppliers subjects us to numerous risks, including possible interruptions in supply, which could adversely affect our business. Our business is vulnerable to the availability of raw materials, as well as our ability to forecast customer demand and manage production capacity. The manufacturing facilities, supply channels or other business operations of the Company and our suppliers may be subject to disruption from events beyond our control. Our future results may be affected by our operational execution, including our ability to achieve cost savings as a result of any current or future restructuring efforts.   If our goodwill and indefinite-lived intangible assets become impaired, we will be required to record impairment charges, which may be significant. Sales of certain of our products are seasonal and adverse weather conditions during our peak selling seasons for certain auto care products could have a material adverse effect. We may use artificial intelligence in our business, which could result in reputational harm, competitive harm, and legal liability, and adversely affect our operations. A failure of a key information technology system could adversely impact our ability to conduct business. We rely significantly on information technology and any inadequacy, interruption, theft or loss of data, malicious attack, integration failure, failure to maintain the security, confidentiality or privacy of sensitive data residing on our systems or other security failure of that technology could harm our ability to effectively operate our business and damage the reputation of our brands. We may not be able to attract, retain and develop key employees, as well as effectively manage human capital resources. We have significant debt obligations that could adversely affect our business. Our credit ratings are important to our cost of capital. We may experience losses or be subject to increased funding and expenses related to our pension plans. The estimates and assumptions on which our financial projections are based may prove to be inaccurate, which may cause our actual results to materially differ from our projections, which may adversely affect our future profitability, cash flows and stock price. If we pursue strategic acquisitions, divestitures or joint ventures, we might experience operating difficulties, dilution, and other consequences that may harm our business, financial condition, and operating results, and we may not be able to successfully consummate favorable transactions or successfully integrate acquired businesses. Our business involves the potential for product liability claims, labeling claims, commercial claims and other legal claims against us, which could affect our results of operations and financial condition and result in product recalls or withdrawals. Our business is subject to increasing government regulations in both the U.S. and abroad that could impose material costs.  Section 45X of the Internal Revenue Code contains production tax credits for certain battery components. Our ability to benefit from Section 45X production tax credits is not guaranteed and is dependent upon the federal government's ongoing implementation, guidance, regulations, or rulemakings. Increased focus by governmental and non-governmental organizations, customers, consumers and shareholders on sustainability issues, including those related to climate change, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. We are subject to environmental laws and regulations that may expose us to significant liabilities and have a material adverse effect on our results of operations and financial condition. We are subject to uncertainties regarding the IEEPA tariff refunds, including the timing of these refunds. In addition, other risks and uncertainties not presently known to us or that we consider immaterial could affect the accuracy of any such forward-looking statements. The list of factors above is illustrative, but by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Additional risks and uncertainties include those detailed from time to time in our publicly filed documents, including those described under the heading "Risk Factors" in our Form 10-K filed with the Securities and Exchange Commission on November 18, 2025.

ENERGIZER HOLDINGS, INC.

CONSOLIDATED STATEMENT OF EARNINGS

(Condensed)

(In millions, except per share data - Unaudited)

For the Quarters Ended March
31,

For the Six Months Ended
March 31,

2026

2025

2026

2025

Net sales

$          643.3

$          662.9

$      1,422.2

$      1,394.6

Cost of products sold (1) (2)

384.5

403.9

906.8

866.0

Gross profit

258.8

259.0

515.4

528.6

Selling, general and administrative expense (1)

133.1

136.0

282.4

267.3

Advertising and sales promotion expense

19.0

20.8

68.2

74.2

Research and development expense

7.6

8.1

15.4

16.1

Amortization of intangible assets

12.5

14.7

26.5

29.4

Interest expense

39.3

38.0

78.4

75.0

Loss on extinguishment/modification of debt

—

5.2

0.9

5.3

Other items, net (3)

25.6

(0.2)

26.7

(5.2)

Earnings before income taxes

21.7

36.4

16.9

66.5

Income tax provision

11.6

8.1

10.2

15.9

Net earnings

$           10.1

$           28.3

6.7

50.6

Basic net earnings per common share

$           0.15

$           0.39

$         0.10

$         0.70

Diluted net earnings per common share

$           0.15

$           0.39

$         0.10

$         0.69

Weighted average shares of common stock - Basic

68.5

72.2

68.5

72.1

Weighted average shares of common stock - Diluted

69.1

73.3

69.2

73.3

(1) See the attached Supplemental Schedules - Non-GAAP Reconciliations, which break out the Restructuring and related costs, Network transition costs and Acquisition and integration costs included within these lines.

(2) During the quarter and six months ended March 31, 2026, the Company recorded a benefit to cost of goods sold of $47.6 million for the estimated refund of the tariffs previously paid under IEEPA associated with sold inventory.

(3) During the quarter and six months ended March 31, 2026, the Company recorded a non-cash settlement loss on the termination of the U.K. Pension plan of $26.1 within Other items, net.

ENERGIZER HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(Condensed)

(In millions - Unaudited)

Assets

March 31,
2026

September 30,
2025

Current assets

Cash and cash equivalents

$                  172.5

$                  236.2

     Trade receivables

309.6

404.2

Inventories

743.6

781.2

Other current assets

273.8

257.5

Total current assets

$                1,499.5

$                1,679.1

Property, plant and equipment, net

392.8

403.0

Operating lease assets

85.8

93.2

Goodwill

1,048.1

1,051.2

Other intangible assets, net

979.3

1,005.5

Deferred tax assets

166.3

166.6

Other assets

227.3

158.1

Total assets

$                4,399.1

$                4,556.7

Liabilities and Shareholders' Equity

Current liabilities

Current maturities of long-term debt

$                     8.6

$                     8.6

Current portion of finance leases

1.6

1.5

Notes payable

0.5

13.7

Accounts payable

393.4

402.2

Current operating lease liabilities

12.2

16.2

Other current liabilities

315.7

352.8

Total current liabilities

$                  732.0

$                  795.0

Long-term debt

3,304.6

3,407.9

Operating lease liabilities

79.1

84.8

Deferred tax liabilities

9.6

6.1

Other liabilities

100.6

93.0

Total liabilities

$                4,225.9

$                4,386.8

Shareholders' equity

Common stock

0.8

0.8

Additional paid-in capital

594.4

603.5

Retained earnings

47.9

87.0

Treasury stock

(280.2)

(295.8)

Accumulated other comprehensive loss

(189.7)

(225.6)

Total shareholders' equity

$                  173.2

$                  169.9

Total liabilities and shareholders' equity

$                4,399.1

$                4,556.7

ENERGIZER HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Condensed)

(In millions - Unaudited)

For the Six Months Ended
March 31,

2026

2025

Cash Flow from Operating Activities

Net earnings

$             6.7

$           50.6

Non-cash integration and restructuring charges

24.4

5.2

Depreciation and amortization

62.7

62.7

Production credits

22.8

—

IEEPA tariff refund receivable

(49.9)

—

Deferred income taxes

3.6

2.6

Share-based compensation expense

16.0

13.4

Settlement loss on U.K. pension plan termination

26.1

—

Loss on extinguishment of debt

0.9

1.1

Exchange loss/(gain) included in income

3.1

(3.4)

Non-cash items included in income, net

5.7

5.7

Other, net

(15.3)

(8.0)

Changes in current assets and liabilities used in operations

41.0

(65.7)

Net cash from operating activities

$          147.8

$           64.2

Cash Flow from Investing Activities

Capital expenditures

(43.0)

(55.6)

Proceeds from sale of assets

1.1

—

Acquisitions, net of cash acquired

—

(0.1)

Net cash used by investing activities

$          (41.9)

$          (55.7)

Cash Flow from Financing Activities

Cash proceeds from issuance of debt with original maturities greater than 90 days (1)

—

198.2

Payments on debt with maturities greater than 90 days (1)

(95.0)

(220.7)

Net (decrease)/increase in debt with original maturities of 90 days or less

(14.5)

0.4

Debt issuance costs

(1.5)

(6.3)

Payment of acquisition indemnification hold back

(0.7)

(0.5)

Common stock purchased (inclusive of excise tax of $0.9)

(5.4)

—

Dividends paid on common stock

(43.9)

(45.3)

Taxes paid for withheld share-based payments

(8.0)

(7.5)

Net cash used by financing activities

$         (169.0)

$          (81.7)

Effect of exchange rate changes on cash

$            (0.6)

$            (4.4)

Net decrease in cash, cash equivalents, and restricted cash

$          (63.7)

$          (77.6)

Cash, cash equivalents, and restricted cash, beginning of period

236.2

216.9

Cash, cash equivalents, and restricted cash, end of period

$          172.5

$          139.3

(1)  Represents cash inflows and outflows due to changes in term loan lender composition in the six months ended March 31, 2025.

ENERGIZER HOLDINGS, INC.
Reconciliation of GAAP and Non-GAAP Measures
For the Quarter and Six months ended March 31, 2026

The Company reports its financial results in accordance with accounting principles generally accepted in the U.S. ("GAAP").  However, management believes that certain non-GAAP financial measures provide users with additional meaningful comparisons to the corresponding historical or future period, and are used for management incentive compensation. These non-GAAP financial measures exclude items that are not reflective of the Company's on-going operating performance, such as restructuring and related costs, network transition costs, acquisition and integration costs, a litigation matter, FY23 & FY24 production credits, impairment of intangible assets, the settlement loss on the U.K. pension plan termination and the loss on extinguishment/modification of debt. In addition, these measures help investors to analyze year over year comparability when excluding currency fluctuations as well as other Company initiatives that are not on-going.  We believe these non-GAAP financial measures are an enhancement to assist investors in understanding our business and in performing analysis consistent with financial models developed by research analysts. Investors should consider non-GAAP measures in addition to, not as a substitute for, or superior to, the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures used by other companies due to possible differences in methods and in the items being adjusted.

We provide the following non-GAAP measures and calculations, as well as the corresponding reconciliation to the closest GAAP measure in the following supplemental schedules:

Segment Profit. This amount represents the operations of our two reportable segments including allocations for shared support functions. General corporate and other expenses, amortization expense, interest expense, loss on extinguishment/modification of debt, other items, net, restructuring and related costs, network transition costs and acquisition and integration costs have all been excluded from segment profit. 

Adjusted Net Earnings and Adjusted Diluted Net Earnings per Common Share (EPS). These measures exclude the impact of restructuring and related costs, network transition costs, costs related to acquisition and integration, the settlement loss on the U.K. pension plan termination and the loss on extinguishment/modification of debt.

Non-GAAP Tax Rate. This is the tax rate when excluding the pre-tax impact of restructuring and related costs, network transition costs, costs related to acquisition and integration, the settlement loss on the U.K. pension plan termination and the loss on extinguishment/modification of debt, as well as the related tax impact for these items, calculated utilizing the statutory rate for the jurisdictions where the impact was incurred.

Organic.  This is the non-GAAP financial measurement of the change in Net sales or Segment profit that excludes or otherwise adjusts for the Acquisition impact, the Change in highly inflationary markets and impact of currency from the changes in foreign currency exchange rates as defined below:

Acquisition Impact. The Company completed the APS acquisition on May 2, 2025. These adjustments include the impact of the operations associated with the acquired branded battery business. The Company transitioned from these branded businesses to legacy brands by December 31, 2025. This does not include the impact of acquisition and integration costs associated with this acquisition.

Change in highly inflationary markets. The Company is presenting separately all changes in sales and segment profit from our Egypt and Argentina affiliates due to the designation of the economies as highly inflationary as of October 1, 2024 and July 1, 2018, respectively.

Impact of currency. The Company evaluates the operating performance of our Company on a currency neutral basis. The Impact of Currency is the change in foreign currency exchange rates year-over-year on reported results, which is calculated by comparing the value of current year foreign operations at the current period USD exchange rate versus the value of current year foreign operations at the prior period USD exchange rate. The impact of currency also includes (gains)/losses of currency hedging programs, and it excludes highly inflationary markets.

Adjusted Comparisons. Detail for Adjusted Gross profit, Adjusted Gross margin, adjusted SG&A, adjusted SG&A as percent of Net sales and Adjusted Other Items, net are also supplemental non-GAAP measure disclosures. These measures exclude the impact of restructuring and related costs, network transition costs, acquisition and integration costs and the settlement loss on the U.K. pension plan termination.

EBITDA and Adjusted EBITDA. EBITDA is defined as (loss)/earnings before Income tax provision, Interest expense, the Loss on extinguishment/modification of debt, and depreciation and amortization. Adjusted EBITDA further excludes the impact of the costs related to restructuring, network transition costs, acquisition and integration costs, the settlement loss on the U.K. pension plan termination, a litigation matter, FY23 & FY24 production credits, impairment of intangible assets, and share based payments.

Free Cash Flow. Free Cash Flow is defined as net cash provided by operating activities reduced by capital expenditures, net of the proceeds from asset sales.

Net Debt. Net Debt is defined as total Company debt, less Cash and cash equivalents.

Currency-neutral. Currency-neutral excludes the Impact of currency as defined above on key measures. Highly inflationary markets are excluded from this calculation.

Operations for Energizer are managed via two product segments: Batteries & Lights and Auto Care. Energizer's operating model includes a combination of standalone and shared business functions between the product segments, varying by country and region of the world. Shared functions include the sales and marketing functions, as well as human resources, IT and finance shared service costs. Energizer applies a fully allocated cost basis, in which shared business functions are allocated between segments. Such allocations are estimates, and may not represent the costs of such services if performed on a standalone basis. Segment sales, significant expenses and profitability for the quarters and six months ended March 31, 2026 and 2025 are presented below:

Quarters Ended March 31,

Batteries & Lights

 Auto Care

Total

2026

2025

2026

2025

2026

2025

Segment Net sales

$     473.2

$     488.0

$     170.1

$     174.9

$     643.3

$     662.9

Segment Cost of products sold

248.1

284.3

109.3

108.2

357.4

392.5

Segment Advertising and promotion expense

12.2

14.3

6.8

6.5

19.0

20.8

Other segment items

79.2

77.1

25.4

25.0

104.6

102.1

Segment profit

$     133.7

$     112.3

$      28.6

$      35.2

$     162.3

$     147.5

Segment Depreciation and amortization

$      15.0

$      12.6

$       3.6

$       3.6

$      18.6

$      16.2

Six Months Ended March 31,

Batteries & Lights

 Auto Care

Total

2026

2025

2026

2025

2026

2025

Segment Net sales

$  1,158.4

$  1,120.4

$     263.8

$     274.2

$  1,422.2

$  1,394.6

Segment Cost of products sold

689.9

664.5

174.5

166.7

864.4

831.2

Segment Advertising and promotion expense

55.8

61.7

12.4

12.5

68.2

74.2

Other segment items

173.3

162.6

39.2

39.3

212.5

201.9

Segment profit

$     239.4

$     231.6

$      37.7

$      55.7

$     277.1

$     287.3

Segment Depreciation and amortization

$      29.7

$      26.9

$       6.5

$       6.4

$      36.2

$      33.3

Reconciliation of Total segment profit to earnings before income taxes:

Quarters Ended March 31,

Six Months Ended March 31,

2026

2025

2026

2025

Total segment profit

$         162.3

$         147.5

$         277.1

$         287.3

General corporate & other expenses (1)

(30.1)

(30.5)

(63.2)

(57.9)

Restructuring and related costs (2)

(31.5)

(17.6)

(62.4)

(37.9)

Network transition costs (3)

—

(2.7)

—

(16.7)

Acquisition and integration costs (2)

(1.6)

(2.3)

(2.1)

(3.5)

Amortization of intangible assets

(12.5)

(14.7)

(26.5)

(29.4)

Interest expense

(39.3)

(38.0)

(78.4)

(75.0)

Loss on extinguishment/modification of debt

—

(5.2)

(0.9)

(5.3)

Settlement loss on U.K. pension plan termination (4)

(26.1)

—

(26.1)

—

Other items, net - Adjusted (5)

0.5

(0.1)

(0.6)

4.9

Total earnings before income taxes

$          21.7

$          36.4

$          16.9

$          66.5

(1)   Recorded in SG&A on the Consolidated (Condensed) Statement of Earnings.

(2)   See the Supplemental Schedules - Non-GAAP Reconciliations for the line items where these charges are recorded in the Consolidated (Condensed) Statement of Earnings.

(3)   This represents incremental network transition costs, primarily related to freight and third-party packaging support, to maintain business continuity and service our customers as the Company decommissions certain facilities and relocates production and packaging lines as part of Project Momentum. These costs were recorded in Cost of products sold on the Consolidated (Condensed) Statement of Earnings.

(4)   During the quarter ended March 31, 2026, the Company terminated the U.K. pension plan and recorded a non-cash settlement loss on the termination of the plan within Other items, Net.

(5)   See the Supplemental Non-GAAP reconciliation for the Other items, net reconciliation between the reported and adjusted balances.

Energizer Holdings, Inc.

Supplemental Schedules - GAAP EPS to Adjusted EPS Reconciliation

For the Quarter and Six months ended March 31, 2026

(In millions, except per share data - Unaudited)

For the Quarters Ended
March 31,

For the Six Months Ended
March 31,

2026

2025

2026

2025

Net earnings

$          10.1

$          28.3

$           6.7

$          50.6

Pre-tax adjustments

Restructuring and related costs (1)

31.5

17.6

62.4

37.9

Network transition costs (1)

—

2.7

—

16.7

Acquisition and integration (1)

1.6

2.3

2.1

3.5

Loss on extinguishment/modification of debt

—

5.2

0.9

5.3

Settlement loss on U. K. pension plan termination (1)

26.1

—

26.1

—

Total adjustments, pre-tax

$          59.2

$          27.8

$          91.5

$          63.4

Total adjustments, after tax (2)

$          55.0

$          21.1

$          79.7

$          48.2

Adjusted Net earnings (2)

$          65.1

$          49.4

$          86.4

$          98.8

Diluted net earnings per common share

$          0.15

$          0.39

$          0.10

$          0.69

Adjustments  (per common share)

Restructuring and related costs

0.39

0.18

0.73

0.39

Network transition costs

—

0.03

—

0.18

Acquisition and integration

0.02

0.02

0.03

0.04

Loss on extinguishment/modification of debt

—

0.05

0.01

0.05

Settlement loss on U. K. pension plan termination

0.38

—

0.38

—

Adjusted Diluted net earnings per diluted common share

$          0.94

$          0.67

$          1.25

$          1.35

Weighted average shares of common stock - Diluted

69.1

73.3

69.2

73.3

(1) See Supplemental Schedules - Non-GAAP Reconciliations for the line items where these costs are recorded on the Consolidated (Condensed) Statement of Earnings. 

(2) The effective tax rate for the Adjusted Net earnings and Adjusted Diluted EPS for the quarters ended March 31, 2026 and 2025 was 19.5% and 23.1%, respectively, and for the six months ended March 31, 2026 and 2025 was 20.3% and 23.9%, respectively, as calculated utilizing the statutory rate for where the costs were incurred.

Energizer Holdings, Inc.

Supplemental Schedules - Currency Neutral Results

For the Quarter and Six months ended March 31, 2026

(In millions, except per share data - Unaudited)

For the Quarter Ended

Prior
Quarter
Ended

March 31, 2026

% Change

% Change

As
Reported

Impact of
Currency(1)

Currency
Neutral

March 31,
2025

As
Reported
Basis

Currency
Neutral
Basis

As Reported under GAAP

Diluted net earnings per common share

$     0.15

$       0.05

$       0.10

$       0.39

(61.5) %

(74.4) %

Net earnings

$     10.1

$         3.2

$         6.9

$       28.3

(64.3) %

(75.6) %

As Adjusted (non-GAAP)(2)

Adjusted diluted net earnings per common share

$     0.94

$       0.05

$       0.89

$       0.67

40.3 %

32.8 %

Adjusted EBITDA

$   158.6

$         3.9

$      154.7

$      140.3

13.0 %

10.3 %

For the Six Months Ended

Prior Six
Months
Ended

March 31, 2026

% Change

% Change

As
Reported

Impact of
Currency(1)

Currency
Neutral

March 31,
2025

As
Reported
Basis

Currency
Neutral
Basis

As Reported under GAAP

Diluted net earnings per common share

$     0.10

$       0.10

$         —

$       0.69

(85.5) %

NM(3)

Net earnings

$      6.7

$         6.7

$         —

$       50.6

(86.8) %

NM(3)

As Adjusted (non-GAAP)(2)

Adjusted diluted net earnings per common share

$     1.25

$       0.10

$       1.15

$       1.35

(7.4) %

(14.8) %

Adjusted EBITDA

$   265.5

$         8.4

$      257.1

$      281.0

(5.5) %

(8.5) %

(1) The Impact of Currency is the change in foreign currency exchange rates year-over-year on reported results, which is calculated by comparing the value of current year foreign operations at the current period USD exchange rate versus the value of current year foreign operations at the prior period USD exchange rate. The impact of currency also includes gains/(losses) of currency hedging programs, and it excludes highly inflationary markets.

(2) See supplemental schedules - Non-GAAP Reconciliations for full reconciliations of the Company's non-GAAP adjusted amounts.

(3) These percentages calculations are not meaningful.

Energizer Holdings, Inc.

Supplemental Schedules - Segment Sales and Profit

For the Quarter and Six Months Ended March 31, 2026

(In millions - Unaudited)

Net sales

Q1'26

% Chg

Q2'26

% Chg

Six 
Months
'26

% Chg

Batteries & Lights

Net sales - prior year

$    632.4

$    488.0

$   1,120.4

Organic

(24.3)

(3.8) %

(28.8)

(5.9) %

(53.1)

(4.7) %

Acquisition impact

64.6

10.2 %

2.1

0.4 %

66.7

6.0 %

Change in highly inflationary markets

0.2

— %

(1.0)

(0.2) %

(0.8)

(0.1) %

Impact of currency

12.3

1.9 %

12.9

2.7 %

25.2

2.2 %

Net sales - current year

$    685.2

8.3 %

$    473.2

(3.0) %

$   1,158.4

3.4 %

Auto Care

Net sales - prior year

$      99.3

$    174.9

$     274.2

Organic

(6.9)

(6.9) %

(7.8)

(4.5) %

(14.7)

(5.4) %

Change in highly inflationary markets

(0.1)

(0.1) %

(0.1)

(0.1) %

(0.2)

(0.1) %

Impact of currency

1.4

1.4 %

3.1

1.9 %

4.5

1.7 %

Net sales - current year

$      93.7

(5.6) %

$    170.1

(2.7) %

$     263.8

(3.8) %

Total Net Sales

Net sales - prior year

$    731.7

$    662.9

$   1,394.6

Organic

(31.2)

(4.3) %

(36.6)

(5.5) %

(67.8)

(4.9) %

Acquisition impact

64.6

8.8 %

2.1

0.3 %

66.7

4.8 %

Change in highly inflationary markets

0.1

— %

(1.1)

(0.2) %

(1.0)

(0.1) %

Impact of currency

13.7

2.0 %

16.0

2.4 %

29.7

2.2 %

Net sales - current year

$    778.9

6.5 %

$    643.3

(3.0) %

$   1,422.2

2.0 %

Energizer Holdings, Inc.

Supplemental Schedules - Segment Sales and Profit

For the Quarter and Six Months Ended March 31, 2026

(In millions - Unaudited)

Segment profit

Q1'26

% Chg

Q2'26

% Chg

Six
Months
'26

% Chg

Batteries & Lights

Segment profit - prior year

$       119.3

$  112.3

$  231.6

Organic

(23.0)

(19.3) %

21.7

19.3 %

(1.3)

(0.6) %

Acquisition impact

5.3

4.4 %

(2.1)

(1.9) %

3.2

1.4 %

Change in highly inflationary markets

(0.1)

(0.1) %

—

— %

(0.1)

— %

Impact of currency

4.2

3.6 %

1.8

1.7 %

6.0

2.6 %

Segment profit - current year

$       105.7

(11.4) %

$  133.7

19.1 %

$  239.4

3.4 %

Auto Care

Segment profit - prior year

$         20.5

$    35.2

$    55.7

Organic

(12.1)

(59.0) %

(8.1)

(23.0) %

(20.2)

(36.3) %

Change in highly inflationary markets

(0.1)

(0.5) %

—

— %

(0.1)

(0.2) %

Impact of currency

0.8

3.9 %

1.5

4.2 %

2.3

4.2 %

Segment profit - current year

$          9.1

(55.6) %

$    28.6

(18.8) %

$    37.7

(32.3) %

Total Segment Profit

Segment profit - prior year

$       139.8

$  147.5

$  287.3

Organic

(35.1)

(25.1) %

13.6

9.2 %

(21.5)

(7.5) %

Acquisition impact

5.3

3.8 %

(2.1)

(1.4) %

3.2

1.1 %

Change in highly inflationary markets

(0.2)

(0.1) %

—

— %

(0.2)

(0.1) %

Impact of currency

5.0

3.5 %

3.3

2.2 %

8.3

2.9 %

Segment profit - current year

$       114.8

(17.9) %

$  162.3

10.0 %

$  277.1

(3.6) %

Energizer Holdings, Inc.

Supplemental Schedules - Non-GAAP Reconciliations

For the Quarter and Six Months Ended March 31, 2026

(In millions - Unaudited)

Gross profit

Q1'26

Q2'26

Q1'25

Q2'25

Q2'26 YTD

Q2'25 YTD

Net sales

$     778.9

$     643.3

$     731.7

$     662.9

$    1,422.2

$    1,394.6

Reported Cost of products sold

522.3

384.5

462.1

403.9

906.8

866.0

Gross profit

$     256.6

$     258.8

$     269.6

$     259.0

$     515.4

$     528.6

Gross margin

32.9 %

40.2 %

36.8 %

39.1 %

36.2 %

37.9 %

Adjustments

Restructuring and related costs

15.3

27.1

9.4

8.7

42.4

18.1

Network transition costs

—

—

14.0

2.7

—

16.7

Cost of products sold - adjusted

507.0

357.4

438.7

392.5

864.4

831.2

Adjusted Gross profit

$     271.9

$     285.9

$     293.0

$     270.4

$     557.8

$     563.4

Adjusted Gross margin

34.9 %

44.4 %

40.0 %

40.8 %

39.2 %

40.4 %

SG&A

Q1'26

Q2'26

Q1'25

Q2'25

Q2'26 YTD

Q2'25 YTD

Reported SG&A

$     149.3

$     133.1

$     131.3

$     136.0

$     282.4

$     267.3

Reported SG&A % of Net sales

19.2 %

20.7 %

17.9 %

20.5 %

19.9 %

19.2 %

Adjustments

Restructuring and related costs

15.6

4.4

10.9

9.2

20.0

20.1

Acquisition and integration costs

0.5

1.6

1.2

2.3

2.1

3.5

SG&A Adjusted - subtotal

$     133.2

$     127.1

$     119.2

$     124.5

$     260.3

$     243.7

SG&A Adjusted % of Net sales

17.1 %

19.8 %

16.3 %

18.8 %

18.3 %

17.5 %

Other items, net

Q1'26

Q2'26

Q1'25

Q2'25

Q2'26 YTD

Q2'25 YTD

Interest income

$       (0.7)

$       (2.5)

$       (1.2)

$       (0.6)

$       (3.2)

$       (1.8)

Foreign currency exchange loss/(gain)

1.3

1.8

(3.8)

0.4

3.1

(3.4)

Pension cost other than service costs and settlement loss

0.5

0.2

—

—

0.7

—

Other

—

—

—

0.3

—

0.3

Other items, net - Adjusted

$        1.1

$       (0.5)

$       (5.0)

$        0.1

$        0.6

$       (4.9)

Settlement loss on U.K. Pension plan termination

—

26.1

—

—

26.1

—

Restructuring and related costs

—

—

—

(0.3)

—

(0.3)

Total Other items, net

$        1.1

$       25.6

$       (5.0)

$       (0.2)

$       26.7

$       (5.2)

Restructuring and related costs

Q1'26

Q2'26

Q1'25

Q2'25

Q2'26 YTD

Q2'25 YTD

Cost of products sold - Restructuring

$        9.2

$       22.1

$        9.4

$        8.7

$       31.3

$       18.1

Cost of products sold - U.S. operating efficiency project

6.1

5.0

—

—

11.1

—

SG&A - Restructuring costs

15.6

4.4

4.8

3.8

20.0

8.6

SG&A - IT Enablement

—

—

6.1

5.4

—

11.5

Other items, net

—

—

—

(0.3)

—

(0.3)

Total Restructuring and related costs

$       30.9

$       31.5

$       20.3

$       17.6

$       62.4

$       37.9

Acquisition and integration

Q1'26

Q2'26

Q1'25

Q2'25

Q2'26 YTD

Q2'25 YTD

SG&A

0.5

1.6

1.2

2.3

2.1

3.5

Total Acquisition and integration related items

$        0.5

$        1.6

$        1.2

$        2.3

$        2.1

$        3.5

Energizer Holdings, Inc.

Supplemental Schedules - Non-GAAP Reconciliations cont.

For the Quarter Ended March 31, 2026

(In millions - Unaudited)

Q2'26

Q1'26

Q4'25

Q3'25

LTM
3/31/26 (1)

Q2'25

Net earnings/(loss)

$   10.1

$   (3.4)

$   34.9

$  153.5

$       195.1

$    28.3

Income tax provision/(benefit)

11.6

(1.4)

18.5

10.7

39.4

8.1

Earnings/(loss) before income taxes

21.7

(4.8)

53.4

164.2

234.5

36.4

Interest expense

39.3

39.1

40.3

39.0

157.7

38.0

Loss on extinguishment/modification of debt

—

0.9

6.8

—

7.7

5.2

Depreciation & Amortization

31.1

31.6

32.1

31.9

126.7

30.9

EBITDA

$   92.1

$   66.8

$  132.6

$  235.1

$       526.6

$   110.5

Adjustments:

Restructuring and related costs

31.5

30.9

22.8

8.0

93.2

17.6

Network transition costs

—

—

2.1

0.9

3.0

2.7

Acquisition and integration costs

1.6

0.5

1.4

1.3

4.8

2.3

Settlement loss on the U.K. pension plan termination

26.1

—

—

—

26.1

—

FY23 & FY24 production credits

—

—

0.5

(78.5)

(78.0)

—

Litigation matter

—

—

—

(1.7)

(1.7)

—

Impairment of intangible assets

—

—

5.9

—

5.9

—

Share-based payments

7.3

8.7

5.9

6.3

28.2

7.2

Adjusted EBITDA

$  158.6

$ 106.9

$  171.2

$  171.4

$       608.1

$   140.3

(1) LTM defined as the latest 12 months for the period ending March 31, 2026.

For the Six Months Ended March 31,

Free cash flow

2026

2025

Net cash from operating activities

$                    147.8

$                      64.2

Capital expenditures

(43.0)

(55.6)

Proceeds from sale of assets

1.1

—

Free cash flow

$                    105.9

$                       8.6

Net debt

3/31/2026

9/30/2025

Current maturities of long-term debt

$                       8.6

$                       8.6

Current portion of finance leases

1.6

1.5

Notes payable

0.5

13.7

Long-term debt

3,304.6

3,407.9

Total debt per the balance sheet

$                  3,315.3

$                  3,431.7

Cash and cash equivalents

172.5

236.2

Net debt

$                  3,142.8

$                  3,195.5

Energizer Holdings, Inc.

Supplemental Schedules - Non-GAAP Reconciliations cont.

FY 2026 Outlook

(In millions - Unaudited)

Fiscal 2026 Outlook Reconciliation - Adjusted earnings and Adjusted net earnings per common share (EPS)

Fiscal Q3 2026 Outlook

Fiscal Year 2026 Outlook

(in millions, except per share data)

Adjusted net
earnings

Adjusted EPS

Adjusted net
earnings

Adjusted EPS

Fiscal 2026 - GAAP Outlook

$39

to

$49

$0.56

to

$0.71

$126

to

$164

$1.80

to

$2.33

Impacts:

Restructuring and related costs

11

8

0.16

0.13

73

61

1.04

0.87

  Acquisition and integration costs

2

1

0.03

0.01

4

2

0.06

0.02

  Loss on extinguishment/modification of debt

—

—

—

—

2

1

0.03

0.01

Settlement loss on pension plan termination

—

—

—

—

26

26

0.37

0.37

Fiscal 2026 - Adjusted Outlook

$52

to

$58

$0.75

to

$0.85

$231

to

$254

$3.30

to

$3.60

Fiscal 2026 Outlook Reconciliation - Adjusted EBITDA

(in millions, except per share data)

Net earnings

$126

to

$164

Income tax provision

6

to

46

Earnings before income taxes

$132

to

$210

Interest expense

160

150

Loss on extinguishment/modification of debt

2

1

Amortization

55

50

Depreciation 

75

65

EBITDA

$424

to

$476

Adjustments:

Restructuring and related costs

95

80

Acquisition and integration costs

5

3

Settlement loss on pension plan termination

26

26

Share-based payments

30

25

Adjusted EBITDA

$580

to

$610

SOURCE Energizer Holdings, Inc.

Energizer Holdings (ENR - Free Report) reported $643.3 million in revenue for the quarter ended March 2026, representing a year-over-year decline of 3%. EPS of $0.94 for the same period compares to $0.67 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $665.21 million, representing a surprise of -3.29%. The company delivered an EPS surprise of +98.61%, with the consensus EPS estimate being $0.47.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Energizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales by products- Batteries & Lights: $473.2 million versus the three-analyst average estimate of $489.92 million. The reported number represents a year-over-year change of -3%.Net Sales by products- Auto Care: $170.1 million versus $175.29 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.Segment Profit- Auto Care: $28.6 million versus the two-analyst average estimate of $22.42 million.Segment Profit- Batteries & Lights: $133.7 million versus $98.97 million estimated by two analysts on average.View all Key Company Metrics for Energizer here>>>

Shares of Energizer have returned +14.7% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways Energizer posted Q2 EPS of 94 cents, up 40.3% y/y, beating estimates on tariff benefits. ENR sales fell 3% as volumes dropped due to timing shifts, auto care softness and packaging changes.Margins expanded on tariff refunds, pricing and cost actions despite mix issues and higher input costs. Energizer Holdings, Inc. (ENR - Free Report) has posted second-quarter fiscal 2026 adjusted earnings of 94 cents per share, jumping 40.3% year over year and beating the Zacks Consensus Estimate of 47 cents by 100%. The company’s profitability benefited from tariff-related developments and internal margin initiatives.

Net sales of $643.3 million declined 3% from the year-ago quarter and missed the consensus mark of $665 million by 3.3%. Organic net sales declined 5.5%, with the key drag coming from volumes rather than pricing. The metric lagged our prediction of a 4.3% decrease in organic net sales.

ENR's Volume Pressures Reflect Timing & Mix HeadwindsManagement said that volume fell 6.1%, reflecting a shift in the timing of battery orders tied to the plastic-free packaging conversion, a slower start to the auto care selling season and modest impacts of the conflict in the Middle East.

Price realization offered a partial offset. Carryover price increases contributed 0.6%, led primarily by the Batteries & Lights segment, helping cushion the demand-driven shortfall. These dynamics framed the quarter as more timing and mix-driven than purely demand-led, even as reported sales still moved lower year over year.

Energizer's Margin & Cost DetailsIn the fiscal second quarter, adjusted gross profit increased 5.7% year over year to $285.9 million, while the adjusted gross margin expanded 360 basis points to 44.4%, which beat our estimate of 37.9%. The improvement was driven primarily by a $47.6-million tariff refund benefit recorded in cost of goods sold, $11.7 million in production tax credits and benefits from pricing. These gains were partially offset by an unfavorable product mix, higher input costs tied to production inefficiencies from network rebalancing and incremental tariffs incurred during the quarter.

Cost discipline remained a focal point, though the expense mix reflected investment and acquisition effects. Adjusted SG&A expenses rose 2.1% to $127.1 million and, as a percentage of net sales, climbed 100 basis points to 19.8%. We expected adjusted SG&A expenses, as a percentage of net sales, to be 20.1% in the fiscal second quarter. The increase was due to higher costs from the APS business of $3 million, investments in digital transformation and growth initiatives, and unfavorable currency, partially offset by approximately $4 million in Project Momentum savings.

Advertising and promotion expenses decreased 8.7% year over year to $19 million, providing a modest offset to the higher SG&A rate. Advertising and Promotion expenses were 3% of net sales in the fiscal second quarter compared with 3.1% in the same quarter last year.

Adjusted EBITDA grew 13% year over year to $158.6 million, supported by the step-up in adjusted gross margin, and lower A&P and R&D spending. The adjusted EBITDA margin expanded about 350 basis points to 24.7%.

ENR Batteries & Lights Segment’s Margin Expands on ExecutionNet sales in the Batteries & Lights segment decreased 3% year over year to $473.2 million, which missed our estimate of $492.4 million. Organic net sales declined 5.9%, primarily reflecting the timing of shipments tied to the plastic-free packaging transition and a modest impact of the conflict in the Middle East, partially offset by pricing and distribution gains tied to the APS integration.

Segment profit increased 19.1% to $133.7 million, with segment profit margin expanding 530 basis points to 28.3%. Management linked the improvement to pricing, production credits and recognition of anticipated tariff recoveries, which helped offset product mix pressures and input cost challenges tied to ongoing network rebalancing.

Energizer's Auto Care Faces Softness but Improves SequentiallyAuto Care results remained pressured by weaker consumption in certain categories and a tough comparison against the prior-year launch dynamics of Armor All Podium Series. The Auto Care segment posted net sales of $170.1 million, which missed our estimate of $174.7 million and edged down 2.7% year over year, with organic net sales declining 4.5%. Results reflected weaker consumption in certain areas and the lapping of the initial sell-in from the Armor All Podium Series launch, which had boosted the prior-year comparison.

Segment profit declined 18.8% to $28.6 million, while segment profit margin fell 330 basis points to 16.8%. Still, management emphasized a notable sequential margin recovery, citing a 710-basis-point improvement from the prior quarter that included tariff-related benefits. Excluding the tariff benefit, the company noted a sequential improvement of 420 basis points, supported by pricing, production efficiencies and tighter cost discipline.

ENR's Cash Flow Supports Deleveraging & Shareholder ReturnsEnergizer ended the second quarter of fiscal 2026 with cash and cash equivalents of $172.5 million, long-term debt of $3.30 billion, and shareholders’ equity of $173.2 million.

For the first six months of fiscal 2026, Energizer generated $147.8 million in operating cash flow and $105.9 million in free cash flow, representing 7.4% of net sales. Shareholder returns were maintained through dividends, as the company paid out $20.6 million in the quarter, or 30 cents per share, while keeping debt reduction as the top capital allocation priority.

Energizer’s APS Contribution Remains Modest in Q2The Advanced Power Solutions acquisition, completed on May 2, 2025, added a small but measurable lift to reported results in the quarter ended March 31, 2026. Management quantified the APS contribution at $2.1 million in net sales for the period.

While the quarter’s acquisition benefit was not large enough to change the top-line trajectory, ENR continues to position APS integration as part of its broader growth and distribution strategy. The focus remains on improving the quality of distribution and strengthening the branded portfolio as the year progresses.

Energizer's Outlook Tilts to High End of Earnings RangeLooking ahead, growth in the second half of the year is expected to be driven primarily by execution rather than any improvement in the consumer environment. The company sees a clear path to growth based on current category trends, supported by expanded distribution and continued innovation. The Armor All Podium Series has scaled significantly, now reaching more than 25,000 stores from around 15,000 earlier, while Energizer Ultimate Child Shield, launched in March, has already secured distribution across major U.S. and international retailers.

Profitability is expected to improve through the combined impacts of pricing actions and ongoing supply-chain optimization initiatives. These efforts are aimed at strengthening margins while enhancing overall operational efficiency.

In the fiscal third quarter, the company expects low-single-digit organic net sales growth, supported by distribution gains, APS integration progress, innovation within Batteries & Lights, and pricing benefits. The adjusted gross margin is projected to be 40%, reflecting pricing, tariff-related benefits and improved network performance. Adjusted earnings per share are expected between 75 cents and 85 cents (excluding the prior year’s one-time 35 cents per share benefit), which implies low-single-digit growth at the mid-point.

For fiscal 2026, net sales are expected to grow at a low-single-digit rate, while organic net sales are projected to remain roughly flat, with growth returning in the back half. The adjusted gross margin is expected to be 40% to 41%, supported by pricing, supply-chain improvements and tariff-related benefits, with fourth-quarter margins expected to remain above 40%, even after cycling tariff recovery benefits.

ENR expects to deliver full-year adjusted earnings at the high end of the previously issued $3.30-$3.60, with adjusted EBITDA also targeted at the high end of $580-$610 million. The improvement in margins and earnings is largely driven by tariff recoveries, which the company intends to use not only for margin recovery but also to reinvest in initiatives that enhance the durability and long-term strength of earnings.

ENR Stock's Past 3-Month Performance

Image Source: Zacks Investment Research

Shares of this Zacks Rank #3 (Hold) company have lost 16.3% in the past three months compared with the industry’s decline of 9.1%.

Some Better-Ranked BetsWe have highlighted three better-ranked stocks, namely Krispy Kreme Inc. (DNUT - Free Report) , Chefs' Warehouse Holdings, LLC (CHEF - Free Report) and Post Holdings (POST - Free Report) .

Krispy Kreme, together with its subsidiaries, operates as a branded retailer and wholesaler of doughnuts, coffee and other complementary beverages and treats and packaged sweets. It presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

DNUT delivered a trailing four-quarter earnings surprise of 14.6%, on average. The consensus estimate for Krispy Kreme’s current fiscal-year sales and earnings indicates a decline of 8.2% and growth of 120%, respectively, from the year-ago period’s reported figures.

Chefs' Warehouse is a distributor of specialty food products. It currently flaunts a Zacks Rank of 1.

The Zacks Consensus Estimate for Chefs' Warehouse’s current financial-year earnings and revenues implies growth of 24.7% and 8.3%, respectively, from the year-ago actuals. CHEF delivered a trailing four-quarter average earnings surprise of 28.9%.

Post Holdings is a consumer-packaged goods holding company, which is involved in the production of center-of-the-store, refrigerated, foodservice, food ingredient and convenient nutrition product categories. It has a Zacks Rank of 2 (Buy) at present.

The Zacks Consensus Estimate for Post Holdings’ current fiscal-year earnings and revenues implies growth of 0.1% and 2.7%, respectively, from the year-ago actuals. POST delivered a trailing four-quarter average earnings surprise of 19.6%.

A month has gone by since the last earnings report for Energizer Holdings (ENR - Free Report) . Shares have lost about 2% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Energizer due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Energizer Q2 Earnings Top Estimates on Tariff Refund BenefitEnergizer has posted second-quarter fiscal 2026 adjusted earnings of 94 cents per share, jumping 40.3% year over year and beating the Zacks Consensus Estimate of 47 cents by 100%. The company’s profitability benefited from tariff-related developments and internal margin initiatives.

Net sales of $643.3 million declined 3% from the year-ago quarter and missed the consensus mark of $665 million by 3.3%. Organic net sales declined 5.5%, with the key drag coming from volumes rather than pricing.

Management said that volume fell 6.1%, reflecting a shift in the timing of battery orders tied to the plastic-free packaging conversion, a slower start to the auto care selling season and modest impacts of the conflict in the Middle East.

Price realization offered a partial offset. Carryover price increases contributed 0.6%, led primarily by the Batteries & Lights segment, helping cushion the demand-driven shortfall. These dynamics framed the quarter as more timing and mix-driven than purely demand-led, even as reported sales still moved lower year over year.

Energizer's Margin & Cost DetailsIn the fiscal second quarter, adjusted gross profit increased 5.7% year over year to $285.9 million, while the adjusted gross margin expanded 360 basis points to 44.4%, which beat our estimate of 37.9%. The improvement was driven primarily by a $47.6-million tariff refund benefit recorded in cost of goods sold, $11.7 million in production tax credits and benefits from pricing. These gains were partially offset by an unfavorable product mix, higher input costs tied to production inefficiencies from network rebalancing and incremental tariffs incurred during the quarter.

Cost discipline remained a focal point, though the expense mix reflected investment and acquisition effects. Adjusted SG&A expenses rose 2.1% to $127.1 million and, as a percentage of net sales, climbed 100 basis points to 19.8%. The increase was due to higher costs from the APS business of $3 million, investments in digital transformation and growth initiatives, and unfavorable currency, partially offset by approximately $4 million in Project Momentum savings.

Advertising and promotion expenses decreased 8.7% year over year to $19 million, providing a modest offset to the higher SG&A rate. Advertising and Promotion expenses were 3% of net sales in the fiscal second quarter compared with 3.1% in the same quarter last year.

Adjusted EBITDA grew 13% year over year to $158.6 million, supported by the step-up in adjusted gross margin, and lower A&P and R&D spending. The adjusted EBITDA margin expanded about 350 basis points to 24.7%.

ENR Batteries & Lights Segment’s Margin Expands on ExecutionNet sales in the Batteries & Lights segment decreased 3% year over year to $473.2 million, which missed our estimate of $492.4 million. Organic net sales declined 5.9%, primarily reflecting the timing of shipments tied to the plastic-free packaging transition and a modest impact of the conflict in the Middle East, partially offset by pricing and distribution gains tied to the APS integration.

Segment profit increased 19.1% to $133.7 million, with segment profit margin expanding 530 basis points to 28.3%. Management linked the improvement to pricing, production credits and recognition of anticipated tariff recoveries, which helped offset product mix pressures and input cost challenges tied to ongoing network rebalancing.

Energizer's Auto Care Faces Softness but Improves SequentiallyAuto Care results remained pressured by weaker consumption in certain categories and a tough comparison against the prior-year launch dynamics of Armor All Podium Series. The Auto Care segment posted net sales of $170.1 million, which missed our estimate of $174.7 million and edged down 2.7% year over year, with organic net sales declining 4.5%. Results reflected weaker consumption in certain areas and the lapping of the initial sell-in from the Armor All Podium Series launch, which had boosted the prior-year comparison.

Segment profit declined 18.8% to $28.6 million, while segment profit margin fell 330 basis points to 16.8%. Still, management emphasized a notable sequential margin recovery, citing a 710-basis-point improvement from the prior quarter that included tariff-related benefits. Excluding the tariff benefit, the company noted a sequential improvement of 420 basis points, supported by pricing, production efficiencies and tighter cost discipline.

ENR's Cash Flow Supports Deleveraging & Shareholder ReturnsEnergizer ended the second quarter of fiscal 2026 with cash and cash equivalents of $172.5 million, long-term debt of $3.30 billion, and shareholders’ equity of $173.2 million.

For the first six months of fiscal 2026, Energizer generated $147.8 million in operating cash flow and $105.9 million in free cash flow, representing 7.4% of net sales. Shareholder returns were maintained through dividends, as the company paid out $20.6 million in the quarter, or 30 cents per share, while keeping debt reduction as the top capital allocation priority.

Energizer's Outlook Tilts to High End of Earnings RangeLooking ahead, growth in the second half of the year is expected to be driven primarily by execution rather than any improvement in the consumer environment. The company sees a clear path to growth based on current category trends, supported by expanded distribution and continued innovation. The Armor All Podium Series has scaled significantly, now reaching more than 25,000 stores from around 15,000 earlier, while Energizer Ultimate Child Shield, launched in March, has already secured distribution across major U.S. and international retailers.

Profitability is expected to improve through the combined impacts of pricing actions and ongoing supply-chain optimization initiatives. These efforts are aimed at strengthening margins while enhancing overall operational efficiency.

In the fiscal third quarter, the company expects low-single-digit organic net sales growth, supported by distribution gains, APS integration progress, innovation within Batteries & Lights, and pricing benefits. The adjusted gross margin is projected to be 40%, reflecting pricing, tariff-related benefits and improved network performance. Adjusted earnings per share are expected between 75 cents and 85 cents (excluding the prior year’s one-time 35 cents per share benefit), which implies low-single-digit growth at the mid-point.

For fiscal 2026, net sales are expected to grow at a low-single-digit rate, while organic net sales are projected to remain roughly flat, with growth returning in the back half. The adjusted gross margin is expected to be 40% to 41%, supported by pricing, supply-chain improvements and tariff-related benefits, with fourth-quarter margins expected to remain above 40%, even after cycling tariff recovery benefits.

ENR expects to deliver full-year adjusted earnings at the high end of the previously issued $3.30-$3.60, with adjusted EBITDA also targeted at the high end of $580-$610 million. The improvement in margins and earnings is largely driven by tariff recoveries, which the company intends to use not only for margin recovery but also to reinvest in initiatives that enhance the durability and long-term strength of earnings.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -8.27% due to these changes.

VGM ScoresAt this time, Energizer has a average Growth Score of C, a score with the same score on the momentum front. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Energizer has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

2 hours ago

CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat

CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:KO

Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares

2 hours ago

Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,054 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $60.37, for a total transaction of $15,759,829.98. Following the completion of the sale, the insider owned 2,671,855 shares in the company, valued at $161,299,886.35. This represents a 8.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

NYSE:BROS

Read Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in Stock

2 hours ago

Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,055 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $63.02, for a total value of $16,451,686.10. Following the completion of the transaction, the insider owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

NYSE:BROS

Read Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of Stock

2 hours ago

Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 749,999 shares of Dutch Bros stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $60.39, for a total transaction of $45,292,439.61. Following the completion of the sale, the chairman owned 2,671,855 shares of the company's stock, valued at $161,353,323.45. This represents a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:BROS

Read Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) Stock

2 hours ago

Insider Selling: Dutch Bros (NYSE:BROS) Chairman Sells 750,000 Shares of StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 750,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $63.02, for a total value of $47,265,000.00. Following the sale, the chairman owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:BROS

Read Insider Selling: Dutch Bros (NYSE:BROS) Chairman Sells 750,000 Shares of Stock

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

, /PRNewswire/ - DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, will host an Investor Day with financial analysts and institutional investors in New York City on June 11, 2026. 

DXC's President and CEO Raul Fernandez and members of the leadership team will discuss the company's strategy and how DXC is positioning its business to capitalize on the accelerating adoption of AI across the enterprise. The program will highlight key priorities for long-term success, present financial goals and showcase new AI-enabled solutions that are reshaping how the company delivers value for its customers globally.

The presentations will begin at 9:00 a.m. ET and are expected to conclude at approximately 1:00 p.m. A live webcast and replay will be available on DXC's Investor Relations website.

About DXC Technology

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed.  With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world's most complex technology estates.  Learn more on DXC.com.

Forward-Looking Statements

Except for historical information, statements in this document may constitute "forward-looking statements" based on our current assumptions regarding future performance. These statements involve numerous risks, uncertainties, and other factors outside our control that could cause actual results to differ materially, including: inability to effectively manage our sales organization, including execution, pipeline, and talent management; our inability to expand service offerings to address emerging technological trends and competitive pressures; failure to attract and retain key personnel, including artificial intelligence (AI) and technical experts, or maintain partner relationships; risks associated with AI, including adoption, deployment, and governance, reliance on third-party platforms, cybersecurity, privacy, evolving regulations, and competitive displacement; inability to accurately estimate contract costs and timelines, or failure by us or third parties to deliver on commitments; systems failures, catastrophic events, and resulting service interruptions; liability or reputational damage from security breaches, cyber-attacks, or disclosure of confidential or personal data; failure to comply with new or existing laws, regulations, and customer contracts, including those relating to data privacy, economic sanctions, export controls, AI, and environmental, social, and governance (ESG) expectations; failure to maintain our credit rating, manage indebtedness, or raise capital, adversely affecting our liquidity and borrowing costs; risks associated with international operations, including exchange rate fluctuations and geopolitical conflicts (such as in Russia/Ukraine and the Middle East); macroeconomic challenges, including inflation, reduced customer spending, and economic slowdowns affecting deal closures and cost-takeout efforts; inability to compete effectively, maintain customer relationships, collect receivables, or comply with government contracting regulations; failure to succeed in strategic transactions, acquisitions, or partnerships; securities price volatility; supply chain disruptions, supplier non-performance, or increased procurement costs due to trade tensions, tariffs, or hostilities; climate change, natural disasters, and increased scrutiny of ESG initiatives; infringement of intellectual property rights, or inability to procure necessary third-party licenses; failure to achieve expected benefits of restructuring plans, workforce reductions, and automation/AI reliance; failure to maintain effective disclosure controls and internal control over financial reporting; asset impairment charges, including but not limited to intangibles and deferred tax assets; inability to pay dividends or repurchase shares; pending investigations, claims, and disputes; changes in tax rates, tax laws, and the timing and outcome of tax examinations; and risks related to completed strategic transactions. For a written description of these factors, see our Annual Report on Form 10-K for the fiscal year ended March 31, 2026, and any updating information in subsequent SEC filings. Forward-looking statements speak only as of the date made. Except as required by law, we assume no obligation to update or revise any forward-looking statements.

SOURCE DXC Technology Company

La migration vers le cloud permet aux clients de Telenor Sweden de bénéficier d'un centre de contact plus performant

, /PRNewswire/ -- DXC Technology (NYSE : DXC), l'un des principaux partenaires en technologie et d'innovation d'entreprise, a conclu un partenariat avec Telenor Sweden, l'un des principaux fournisseurs de télécommunications de la région nordique, afin de moderniser les opérations de service à la clientèle et de renforcer son parc technologique. S'appuyant sur une relation de longue date, DXC a achevé une migration majeure vers le cloud pour les opérations de service à la clientèle de Telenor Sweden et soutient des efforts plus larges de modernisation des applications.

Pour répondre aux exigences numériques, Telenor a recherché un partenaire possédant une expertise approfondie des télécommunications afin de moderniser les systèmes existants, d'améliorer l'engagement des clients et de construire une base technologique plus évolutive.

DXC a migré les canaux vocaux et de chat de Telenor pour les clients consommateurs et les petites entreprises vers une plateforme de centre de contact moderne et basée sur le cloud. La nouvelle plateforme prend en charge plus de 500 spécialistes simultanés et traite plus de 300 000 appels de clients par mois. Le programme comprenait l'intégration avec des dizaines de systèmes de back-office et la conception de flux d'appels avancés, ce qui a permis une mise en service parfaitement fluide.

En plus de la migration vers le cloud, DXC fournit des services d'application et un soutien au développement pour les applications de service à la clientèle de Telenor afin de réduire la complexité opérationnelle, de rationaliser les processus et d'améliorer les délais de mise sur le marché. Cela crée également une base pour les capacités futures de l'IA.

« Il s'agit de bien plus qu'une simple mise à niveau du centre de contact », déclare Peter Skarendal, directeur général, DXC Sweden. « Nous modernisons également les applications sous-jacentes, ce qui permet à Telenor de continuer à faire évoluer son service à la clientèle et d'intégrer l'IA au fur et à mesure que les cas d'utilisation arrivent à maturité. » 

À propos de DXC Technology

DXC Technology (NYSE : DXC) est l'un des principaux partenaires de technologie et d'innovation qui fournit des logiciels, des services et des solutions aux entreprises mondiales et aux organisations du secteur public, en les aidant à exploiter l'IA pour obtenir des résultats à une époque de changement exponentiel. Fort d'une expertise approfondie dans les services d'infrastructure gérés, la modernisation des applications et les solutions logicielles spécifiques au secteur, DXC modernise, sécurise et exploite certains des parcs technologiques les plus complexes au monde. Pour en savoir plus, consultez le site dxc.com.

CONTACT AVEC LES MÉDIAS : Ashley Houk-Temple, relations avec les médias, [email protected]

Also from this source

Cloud migration scales contact center for Telenor Sweden customers

, /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, has entered partnership with Telenor Sweden, one of the Nordic region's leading telecommunications providers, to modernize customer service operations and strengthen its technology estate. Building on a long-standing relationship, DXC has completed a major cloud migration for Telenor Sweden's customer service operations and is supporting broader application modernization efforts.

To meet digital demands, Telenor sought a partner with deep telecom expertise to modernize legacy systems, enhance customer engagement, and build a more scalable technology foundation.

DXC migrated Telenor's voice and chat channels for consumer and small business customers to a modern, cloud-based contact center platform. The new platform supports more than 500 concurrent specialists and handles more than 300,000 customer calls per month. The program included integration with dozens of back-office systems and the design of advanced call flows, enabling a seamless go-live.

In addition to the cloud migration, DXC is providing application services and development support for Telenor's customer service applications to help reduce operational complexity, streamline processes, and improve time to market. This also creates a foundation for future AI capabilities.

"This is more than a contact center upgrade," said Peter Skarendal, Managing Director, DXC Sweden. "We're also modernizing the applications behind it, which gives Telenor room to keep evolving its customer service and to layer in AI as the use cases mature." 

About DXC Technology 

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world's most complex technology estates. Learn more on dxc.com.

MEDIA CONTACT: Ashley Houk-Temple, Media Relations, [email protected] 

DXC formally elevates its engineering division as a distinct service offering within its Consulting & Engineering Services (CES) organization combining deep domain-specific solutions, a powerful ecosystem of strategic technology partners, and AI-enabled solutions

11,000+ engineers across 29 countries within CES, DXC's broader 40,000-strong Consulting & Engineering Services organization A rapidly growing engineering market where DXC's combination of domain depth, proprietary platforms, and curated partner ecosystem creates a structurally differentiated value proposition Software powering 50M+ vehicles worldwide, trusted by 17 of the world's top 20 banks, and mission-critical infrastructure — evidence of an engineering practice that already operates at global scale , /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced DXC Engineering, a distinct service offering and a foundational pillar of its Consulting & Engineering Services (CES) business. DXC Engineering is built on the 20-year digital engineering heritage of Luxoft—which DXC acquired in 2019—and consists of more than 11,000 highly specialized engineers delivering mission-critical solutions across Financial Services, Automotive, Manufacturing, Telecommunications, Energy and other industries.

DXC Engineering logo The new entity brings together three distinct capabilities: deep domain expertise, an industry-specific/AI partnership ecosystem, and Physical AI-enabled smart product design. DXC Engineering does not separate industry knowledge from technical execution, giving customers a single partner for the challenges that matter most. DXC builds solutions for customers that include a trading risk engine that can navigate real market volatility, an autonomous driving stack that meets functional safety standards, and a real-time telecom network platform that scales. DXC Engineering builds on these with focused investments to harness the potential triggered by AI.

"With DXC Engineering, we are making a deliberate bet and doubling down on DXC's unique engineering DNA. We are in the early stages of the software-defined era, and the time is now for customers to turn R&D into software-defined intelligent systems that will help them win in the marketplace. DXC Engineering is a signal to the market and to our customers that we are elevating the importance of our IP — both human and digital. Our customers look to DXC to design, build, and operate intelligent systems at scale, especially in environments where failure is not an option, and DXC Engineering will accelerate that capability just at the moment it's needed most in the marketplace."

— Ramnath Venkataraman, President, Consulting & Engineering Services, DXC Technology

CAPABILITIES DXC ENGINEERING BRINGS TO MARKET
Domain-specific Solutions:
DXC Engineering operates at both ends of the engineering spectrum: integrating the industry-specific software packages customers depend on, while simultaneously building the proprietary systems — trading engines, risk platforms, digital banking infrastructure — that set them apart. In Financial Services, DXC Engineering supports trading, risk, treasury, payments, digital banking, and regulatory platforms used by leading global institutions. In automotive, this dual model powers AMBER, DXC's proprietary software framework, which reduces vehicle software development cycles by up to 50% and infotainment costs by up to 30%. In other industries, DXC Engineering delivers telecom network modernization, AI-enabled operational platforms, Smart Manufacturing, and industrial engineering solutions supporting critical processes and infrastructure. The combination of deep integration expertise and bespoke engineering enables DXC to execute complex, large-scale transformations with speed, precision, and confidence.

A Robust Partner Ecosystem
DXC Engineering has deliberately built a partner ecosystem spanning the full breadth of what customers need — from silicon and AI compute leaders who unlock hardware-software convergence, to industry platform specialists including Murex, Temenos, and others who define how financial markets, trading operations, and core banking systems run, to a growing cohort of domain-specific technology startups bringing frontier capability into production environments. Across every layer, DXC Engineering adds its own bespoke engineering and enterprise-grade integration that goes further than any single-capability partner working alone.

Physical AI and AI-enabled Intelligent Systems
DXC Engineering applies AI across both enterprise and physical environments to improve automation, resilience, productivity, and operational intelligence. This includes banking and operations platforms, intelligent telecom and infrastructure systems, and advanced operational analytics across industries.

In a physical environment at the core of DXC Engineering's smart product capability is Physical AI — the discipline of engineering intelligent systems where software, hardware, and AI converge in real-world environments

From making autonomous vehicles road-ready to enhancing production line productivity at  unprecedented speed, DXC works with silicon and AI compute leaders, such as NVIDIA to integrate embedded computing power solutions that can make Physical AI come to life for clients in ways that redefine what's possible.

AT SCALE TODAY

Financial services: 17 of the world's top 20 banks served; 350+ banking and capital markets clients across 70 countries; world's largest Murex implementation practice Automotive: software in 50M+ vehicles; active programs with leading European and global OEMs and Tier-1 suppliers via AMBER platform Other focus industries covered by 150+ clients and more than 3000 projects delivered DXC Engineering operates across 29+ countries and 51 delivery sites, with dedicated client-facing teams in North America, Continental Europe, and APJMEA as part of DXC's global CES organization. For more information, visit dxc.com/engineering.

MEDIA CONTACT: Ashley Houk-Temple, Media Relations, [email protected]

Connects financial institutions to fintech ecosystems across payments, digital assets, and embedded finance through a pre‑integrated partner network including Ripple, Euronet, Splitit, and Aptys Solutions, and ArcOne Helps banks launch and scale new services faster by reducing integration complexity across existing core banking systems CoreIgnite is part of DXC GrowthX, focused on helping customers modernize faster, accelerate innovation, and unlock new growth opportunities through digital transformation , /PRNewswire/ - DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced the launch of DXC CoreIgnite, a cloud‑native revenue orchestration platform designed to give financial institutions a single connection point to fintech ecosystems, orchestrate financial workflows, and activate new revenue opportunities — all while working with existing core systems.

DXC CoreIgnite Built to operate across both DXC's Hogan core banking platform and non‑Hogan environments, DXC CoreIgnite enables banks to modernize incrementally while maximizing existing infrastructure investments. Through pre‑built integrations and real‑time orchestration, CoreIgnite provides direct access to payment networks, digital asset ecosystems, embedded finance capabilities, and a growing partner network including Ripple, Euronet, Splitit, Aptys Solutions, and ArcOne.

The financial services industry is being reshaped by embedded finance, digital assets, and real‑time payments — creating new opportunities for growth and customer engagement. Yet many institutions remain constrained by fragmented integrations, legacy architectures, and the cost and complexity of modernization. As competition intensifies, DXC CoreIgnite gives banks the ability to quickly connect partners, launch new offerings, and scale innovation with greater speed and flexibility.

Designed by DXC engineers and powered by decades of banking expertise, CoreIgnite provides a single orchestration layer that helps institutions connect, manage, and scale fintech capabilities without replacing the core systems they rely on every day. Its composable architecture and real‑time execution model reduce integration complexity, accelerate time‑to‑value, and enable banks to introduce new services more efficiently.

Unlike traditional solutions that require custom integrations across multiple providers, CoreIgnite provides technology enablement and orchestration capabilities to help financial institutions support a broad range of use cases including:

Embedded finance Buy Now, Pay Later (BNPL) services Digital assets and stablecoin‑enabled services Payments orchestration across ACH, RTP, FedNow, wire, and card networks "CoreIgnite provides fintech infrastructure for financial institutions looking to innovate faster, scale more flexibly, and compete more effectively in the digital banking economy. With our secure, composable, API‑first platform, banks can connect new capabilities, orchestrate financial workflows, and activate digital financial services without disrupting the core systems they rely on every day. By decoupling innovation from the core, institutions can reduce integration complexity, move faster, and unlock new revenue opportunities at scale." — Sandeep Bhanote, Global Head and General Manager of GrowthX, DXC Technology

DXC CoreIgnite streamlines how banks access and scale fintech services, from onboarding and eligibility to payments and partner management. Institutions can add, switch, and expand capabilities as business needs evolve, helping reduce integration complexity and operational overhead while accelerating time to market.

CoreIgnite builds on the strength of DXC Hogan, the flagship core banking platform that powers more than 300 million deposit accounts and over $5 trillion in deposits worldwide. CoreIgnite is part of DXC GrowthX, DXC's strategic growth business focused on developing industry‑specific software, platforms, and solutions that help customers navigate industry transformation and unlock new sources of growth.

About DXC Technology

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry‑Specific Software Solutions, DXC modernizes, secures, and operates some of the world's most complex technology estates. Learn more at dxc.com.

SOURCE DXC Technology Company

, /PRNewswire/ - DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced If Skadeförsäkring AB, the largest property and casualty insurer in the Nordics, has partnered with DXC to leverage DXC OASIS and to simplify, modernize and unify its technology estate following its acquisition of Topdanmark, a leading Danish insurer.

DXC to Simplify and Strengthen If’s Technology Estate Across the Nordics with DXC OASIS (CNW Group/DXC Technology Company) As insurers integrate acquisitions and scale across markets, technology environments become more fragmented and complex, creating overlapping systems, operational silos and increasing infrastructure complexity that make it harder to deliver resilience, efficiency and consistent operations at scale. The result can be higher costs, slower integration and reduced visibility across critical systems, impacting both operational agility and customer experience. Closing that gap requires a technology partner capable of operating mission-critical systems at scale while consolidating and simplifying the technology estate that underpins day-to-day operations.

Building a More Unified and Resilient Technology Foundation
To achieve its modernization agenda, If chose DXC to operate its mission-critical technology estate, with DXC OASIS providing an intelligent orchestration layer across its multi-country operations in Finland, Sweden, Denmark and the Baltics. The multi-year agreement positions DXC to modernize and operate thousands of the company's compute resources across mainframe, data center and Microsoft Azure hybrid cloud environments, forming the technology backbone of If's day-to-day insurance operations while enhancing governance, security and visibility.

"As part of our strategy, we are building a stronger, more secure and scalable technology foundation across the Nordics and Baltics. Our partnership with DXC Technology enables us to simplify and modernise our infrastructure, consolidate our IT landscape and leverage automation and AI to enhance quality and efficiency. Together, we are building a more resilient, future-ready platform that will enable us to continue delivering stable, and secure services and great experiences to our business and customers," says Hanna Elomaa, Head of IT Operations, If Skadeförsäkring AB

The agreement will also support If's integration of Topdanmark by simplifying and unifying technology operations across the combined organization, reducing operational complexity and improving resilience, efficiency and performance across its infrastructure environment. DXC will also consolidate disparate mainframe and private cloud environments into its Denmark-based data centers and establish hybrid cloud orchestration with Microsoft Azure.

Integrating DXC OASIS

DXC OASIS will provide If with a unified orchestration layer designed to improve visibility, coordination and governance across its technology estate. By bringing together infrastructure operations across multiple vendors and environments, DXC OASIS will help streamline operations, automate workflows and improve reliability across the organization. The platform's agentic AI capabilities will support a new operating model for If's IT operation with proactive monitoring and operational optimization, helping reduce manual effort for IT teams while improving performance and resilience across critical systems, as well improving the overall customer experience.

"If is bringing together operations across multiple markets and environments, and that requires a technology foundation that is resilient, unified and built for scale," said Peter Skarendal, Managing Director, DXC Sweden. "With DXC OASIS, we're helping If simplify and orchestrate its mainframe, data center and cloud environments across multiple vendors as one integrated operation, improving visibility, reducing operational complexity and strengthening performance across the organization. This creates a more agile and resilient foundation that allows If's team to stay focused on delivering seamless experiences for customers while DXC helps power the integration behind the scenes."

About DXC Technology

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world's most complex technology estates. Learn more on dxc.com.

SOURCE DXC Technology Company

DXC is a Global Premier partner in the Claude Partner Network, creating new global domain-specific AI offerings for key industries. Claude is already powering DXC OASIS, the company's AI-native orchestration platform for managed services, now in production with more than 50 joint customers.  With a workforce of over 115,000 across 70 countries, DXC and Anthropic are deepening their existing relationship to bring Claude inside the mission-critical systems and platforms DXC operates for the world's largest enterprises and governments.   Partnership establishes a new DXC workforce of Claude-certified forward-deployed engineers and builders to be embedded directly in customer environments to accelerate agentic AI transformation.  , /PRNewswire/ - DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced a multi-year global partnership with Anthropic, the AI safety company and creator of Claude. Through this joint initiative, DXC becomes one of the few Global Premier partners in the Claude Partner Network.

DXC and Anthropic Announce Multi-Year Global Alliance to Bring AI into Mission-Critical Enterprise Systems Together, the companies will train a dedicated workforce of tens of thousands of forward-deployed, Claude-certified engineers and builders to bring Claude models into production inside the mission-critical technology infrastructure systems DXC operates for the world's largest banks, airlines, insurers, manufacturers, and government agencies. 

The alliance builds on DXC's existing use of Claude in its own operations, including as the primary development tool used to build DXC OASIS, the company's AI-native orchestration platform for managed services. Using Claude models, DXC accelerated DXC OASIS software delivery by an estimated 10x, with more than 95% of code generated by Claude before human review. Claude now serves as the default foundation model powering DXC OASIS's agentic workflows. Launched in April 2026, DXC OASIS is currently deployed across more than 50 customers and will be rolled out across the DXC global customer base. 

The alliance and its investments are built around DXC Xponential, the company's AI blueprint that connects technology with people and processes — while the Anthropic partnership strengthens it with certified Claude expertise and direct access to Anthropic's resources.

"DXC helps the world's largest banks, airlines, insurers, and government agencies put new technology to work. They proved Claude inside their own operations first, under the same security and compliance requirements their customers face. Now we're bringing Claude inside those environments together, industry by industry, with engineers who have already done it themselves." — Paul Smith, Chief Commercial Officer, Anthropic      

"For more than fifty years, DXC and the companies it was built from run the systems that run the world. We know what it takes to deliver in these environments. This alliance with Anthropic combines trust and experience with the most advanced AI technology available and gives our customers something they cannot get anywhere else. We are already using Claude across our own operations and our new DXC OASIS platform. Now we are scaling that capability directly into the mission-critical technology systems we run for our customers. This is a defining moment for DXC and for the industry."

 — Raul Fernandez, President & CEO, DXC Technology

Forward-Deployed Engineers: Recruited by DXC, Certified by Anthropic

At the center of the alliance, DXC is establishing a dedicated team of forward-deployed engineers to work directly inside customer environments. These engineers will be selectively recruited from DXC's existing engineering talent, trained and certified in 90 days through the Anthropic Partner Academy, receiving persistent, daily access to Claude and progressing through increasingly rigorous levels of proficiency in designing, deploying, and governing agentic AI systems. DXC has also developed additional certification curriculum to enhance its engineers' capability to operate in mission-critical environments.

The model reflects DXC's Customer Zero philosophy: the company validated Claude inside its own operations first, under production-grade security and compliance requirements, before bringing that capability to customers.

What's Next: New Offerings
Initial focus areas include insurance, cybersecurity, and application services, where DXC brings significant domain and operational expertise, and Claude's agentic AI capabilities can deliver value fastest inside customers' mission-critical environments.

Insurance: Across organizations, DXC will leverage Claude to deploy agentic solutions and transform core systems aligned to each firm's unique context, operating model, and strategic intent.  Modernization as a Service (MaaS): DXC is using Claude to accelerate large-scale code modernization for enterprise customers, applying agentic AI to analyze, refactor, and transform legacy codebases faster and with greater accuracy than traditional approaches. Cybersecurity: DXC OASIS security engineer sub-agent built on Claude Security will give DXC's cybersecurity team a decisive edge by deploying Claude across security operations centers (SOCs), realizing always-on, AI-driven cyber resilience.   Application Services: DXC is leveraging Claude to develop Anthropic-certified DXC OASIS agents designed to embed Claude directly into the enterprise application maintenance and management environments DXC operates for its customers.  About DXC Technology
DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world's most complex technology estates. Learn more at dxc.com.

SOURCE DXC Technology Company

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating DXC Technology Company (NYSE: DXC) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

DXC Technology Investors: Contact Johnson Fistel
If you purchased DXC Technology securities and suffered losses on your investment, you are encouraged to click here to join the investigation.

For more information, contact Jim Baker at [email protected] or (619) 814-4471.

There is no cost or obligation to you.

Background of the Investigation
DXC Technology is an enterprise technology and innovation company that provides software, services, and solutions to global enterprises and public sector organizations.

On May 7, 2026, after the market closed, DXC reported its fourth quarter and full fiscal year 2026 financial results. The Company reported total revenue of approximately $3.13 billion for the fourth quarter, representing a 1.2% year-over-year decline and a 6.6% decline on an organic basis. DXC also reported fourth quarter bookings of approximately $3.3 billion, down 13.5% year over year.

During the Company’s May 7, 2026 earnings call, management disclosed that DXC’s top-line performance fell short of expectations. The Company stated that it missed its organic revenue guidance by approximately $75 million, or two percentage points, and that this was not just a pipeline and demand issue, but also an execution issue.

Management further disclosed that DXC experienced increased weakening of discretionary spending on short-term services projects, particularly within Global Infrastructure Services. DXC also stated that shorter-term project-based services pressure seen throughout the year continued and worsened during the quarter.

In addition, DXC’s Chief Executive Officer discussed the Company’s performance on large opportunities expected to close before fiscal year-end. Management disclosed that DXC pursued 13 large opportunities during the quarter, representing more than $2 billion of potential total contract value. On a dollar-weighted basis, DXC won 32% of those opportunities, lost 40%, and roughly 28% remained outstanding. The Company’s Chief Executive Officer stated that he personally expected a higher win rate.

DXC also issued fiscal year 2027 guidance projecting continued organic revenue decline of approximately 3% to 5% year over year.

Following these disclosures, DXC’s stock price declined sharply.

In light of these recent disclosures, Johnson Fistel is investigating whether DXC Technology complied with federal securities laws. If you suffered losses, or are a long-term holder of DXC Technology stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud, breaches of fiduciary duties, and other violations of state and federal law.

Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.

Contact

Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471
[email protected] | [email protected]

On April 24, 2026, Vertex Inc VERX shares rose 7.2% today, currently trading at $12.52. The stock has fluctuated within a 52-week range of $10.59 to $42.44, reflecting significant volatility over the past year.

GF Value™ verdict: The current price of $12.52 represents a 65.0% discount to the GF Value™ estimate of $35.82.GF Score™: The stock holds a score of 65/100, indicating an above-average rating.Most notable signal: Insiders have shown confidence by purchasing $6.4M in stock over the last three months, with no selling activity reported. Is VERX Overvalued or Undervalued? The current share price of Vertex Inc VERX at $12.52 is significantly below the GF Value™ estimate of $35.82, suggesting that the stock could be undervalued by approximately 65.0%. This difference indicates a substantial margin of safety for potential investors, as the market price does not reflect the intrinsic value suggested by the GF Value™. However, it is essential to consider that the GF Valuation label indicates a "Possible Value Trap," which means that while the stock appears undervalued based on the GF Value™, there may be underlying issues that could hinder its recovery or growth.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Investors are encouraged to perform thorough due diligence, as the current undervaluation must be assessed against the company's financial health and market conditions.

How Does VERX's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 313.0x 299.9x Forward P/E 17.3x N/A Vertex Inc's current P/E (TTM) ratio stands at 313.0x, which is slightly above its 5-year median of 299.9x. In contrast, the forward P/E ratio of 17.3x suggests a more favorable valuation going forward. This P/E analysis aligns with the GF Value™ verdict, indicating that while the stock is currently trading above its historical valuation metrics, the potential for future earnings growth may warrant consideration. However, the high current P/E could also signal that the market is pricing in significant future growth, which may not materialize.

What Does VERX's GF Score™ Tell Us? Metric Rating GF Score™ 65 Financial Strength 4/10 Profitability 4/10 Growth 8/10 Valuation 2/10 Momentum 2/10 The GF Score™ of 65/100 reflects an above-average rating for Vertex Inc, highlighted primarily by its strong growth rank of 8/10. However, the valuation and momentum ranks are notably weak at 2/10, suggesting potential concerns about the stock's current price performance and overall valuation metrics. The financial strength and profitability ranks are also average, indicating that while the company exhibits growth potential, it may face challenges in maintaining financial stability and profitability in the near term.

What Are Insiders Doing with VERX Stock? Recent insider activity for Vertex Inc shows a strong buying trend, with insiders purchasing $6.4 million worth of shares in the last three months and no reported selling. This pattern of insider buying can be a positive signal, indicating that those with the most knowledge of the company's operations and prospects believe that the stock is undervalued and has significant upside potential. Such confidence from insiders often suggests that they foresee improvements in the company's performance or market conditions.

What This Means for Investors Based on the analysis, Vertex Inc VERX appears to be undervalued according to GF Value™, with a substantial margin of safety. However, potential investors should exercise caution due to the "Possible Value Trap" label, which implies that while the stock seems attractive at its current price, underlying financial metrics may present risks that need further investigation.

For the complete analysis, visit the Vertex Inc VERX stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is VERX's GF Score™?

VERX's GF Score™ is 65/100, indicating an above-average rating based on key aspects affecting long-term returns.

Is VERX overvalued or undervalued?

VERX is currently considered undervalued, with a GF Value™ estimate suggesting a significant upside potential compared to its current price.

What is VERX's P/E ratio?

VERX's P/E (TTM) is 313.0x, which is slightly above its 5-year median of 299.9x, indicating that the stock is trading at higher valuation multiples compared to its historical averages.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

– Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 –

– Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for povetacicept in IgA nephropathy, following positive Phase 3 interim analysis data; initiated Phase 3 portion of Phase 2/3 study in primary membranous nephropathy and Phase 2 proof-of-concept study in generalized myasthenia gravis –

– Continued progress across broad clinical-stage pipeline, including label expansion of eligible U.S. patient populations for ALYFTREK and TRIKAFTA and completion of U.S. regulatory submission for approval of CASGEVY in children ages 5 to less than 12 years old with SCD or TDT–

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance.

“Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “CASGEVY and JOURNAVX delivered more than 25 percent of our growth this quarter, underscoring the strength of the increasingly diversified revenue base. As we execute across the commercial portfolio and pipeline and build our fourth franchise in nephrology, Vertex is poised to continue to deliver for patients and create long-term value.”

First Quarter 2026 Results

Total revenue increased 8% to $2.99 billion compared to the first quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas. In the U.S., total revenue increased 7% to $1.78 billion due to continued strong CF patient demand, including from new initiations of ALYFTREK; higher realized net prices in CF versus the prior year; and contributions from CASGEVY and JOURNAVX. Outside the U.S., total revenue increased 9% to $1.21 billion due to strong CF performance across multiple geographies, including ALYFTREK uptake, increased CASGEVY revenue, and a favorable impact from foreign exchange.

Combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expenses were $1.5 billion and $1.3 billion, respectively, in the first quarter of 2026, compared to $1.4 billion and $1.2 billion, respectively, for the first quarter of 2025. These increases were primarily due to commercial investment to support the launch of JOURNAVX in acute pain and the build-out of the renal franchise, led by povetacicept in IgAN.

GAAP effective tax rate was 17.7% compared to 11.5% for the first quarter of 2025, primarily due to higher excess tax benefits related to stock-based compensation and lower pre-tax book income in the first quarter of 2025 due to an intangible asset impairment charge.

Non-GAAP effective tax rate was 19.6% compared to 18.8% for the first quarter of 2025.

GAAP net income was $1.0 billion compared to $646 million for the first quarter of 2025, as a result of increased product revenue, partially offset by increased operating expenses and income tax expenses. In addition, first quarter 2025 results included a $379.0 million intangible asset impairment charge.

Non-GAAP net income was $1.1 billion, an increase of $93 million compared to the first quarter of 2025, primarily due to increased product revenue, partially offset by increased operating and income tax expenses in the first quarter of 2026.

Cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion, compared to $12.3 billion as of December 31, 2025. The increase was primarily due to cash flows from operating activities, partially offset by repurchases of Vertex’s common stock pursuant to its share repurchase programs.

Full Year 2026 Financial Guidance

Vertex today reiterated full year 2026 financial guidance. Vertex’s total revenue guidance of $12.95 billion to $13.1 billion includes expectations for continued growth in CF, including the ongoing U.S. rollout and ex-U.S. launches of ALYFTREK, as well as $500 million or more in revenue from non-CF products, including increased patient infusions of CASGEVY through Vertex’s global ATC network and growth in prescriptions and revenue from the second year of the launch of JOURNAVX. Vertex’s guidance for both combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses includes expectations for continued investment in multiple mid- and late-stage clinical development programs and commercialization capabilities, and approximately $100 million of currently anticipated AIPR&D expenses. This guidance also includes an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations.

Vertex’s financial guidance is summarized below:

Current FY 2026

Previous FY 2026

Total revenue

Unchanged

$12.95 to $13.1 billion

Non-CF product revenue

Unchanged

$0.5 billion or greater

Combined GAAP R&D, AIPR&D and SG&A expenses *

Unchanged

$6.3 to $6.45 billion

Combined non-GAAP R&D, AIPR&D and SG&A expenses*

Unchanged

$5.65 to $5.75 billion

Non-GAAP effective tax rate

Unchanged

19.5% to 20.5%

*The difference between the combined GAAP R&D, AIPR&D and SG&A expenses and the combined non-GAAP R&D, AIPR&D and SG&A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense.

**Combined GAAP and non-GAAP R&D, AIPR&D and SG&A expenses guidance includes approximately $100 million of AIPR&D expenses.

Key Business Highlights

Marketed Products

Cystic Fibrosis (CF) Portfolio

Vertex has worked for more than 20 years to discover and develop medicines to treat the underlying cause of CF. Vertex CFTR modulators can treat approximately 95 percent of all people living with CF in core markets, including patients as young as one month old. ALYFTREK, the newest marketed CFTR modulator, is approved in the U.S., the United Kingdom (U.K.), the European Union (EU), Canada, New Zealand, Switzerland, Australia, and Israel for the treatment of patients 6 years and older. Vertex anticipates that the number of CF patients taking its medicines will continue to grow through new approvals and reimbursement agreements, treatment of younger patients, increased survival, and expansion into additional geographies. Recent progress includes:

The U.S. Food and Drug Administration (FDA) recently approved label extensions for ALYFTREK and TRIKAFTA, expanding availability of these medicines to approximately 95% of all people with CF in the United States. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. With this approval, approximately 800 more people with CF in the U.S. are now eligible for the first time for a medicine that treats the underlying cause of their disease. Vertex recently secured reimbursement agreements for ALYFTREK in Scotland, Spain, Sweden, Switzerland, New Zealand, Israel, and Finland and is working to secure access for eligible patients in additional countries. Following recently reported positive results from the study of ALYFTREK in children ages two to five years, Vertex is on track to submit for global regulatory approvals in the first half of 2026. Vertex continues to enroll and dose the pivotal study of ALYFTREK in children ages one to less than two years. Following recently reported positive results from the study of TRIKAFTA in children ages one to less than two years, Vertex has begun submissions for global regulatory approvals for TRIKAFTA in this age group. CASGEVY for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)

CASGEVY is a non-viral, ex vivo, CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT that has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved in the U.S., the U.K., the EU, the Kingdom of Saudi Arabia (KSA), the Kingdom of Bahrain, Qatar, Canada, Switzerland, the United Arab Emirates (UAE), and Kuwait for patients 12 years and older with SCD or TDT. In total, there are more than 60,000 eligible patients in these countries, including approximately 37,000 in North America and Europe and more than 23,000 in the Middle East. Recent highlights include:

Vertex recorded first quarter 2026 CASGEVY revenue of $43 million. Vertex recently secured a pricing agreement for CASGEVY for eligible patients with SCD or TDT in Germany. Vertex is now working through final implementation to provide long-term reimbursed access to patients at a sustainable price. Vertex completed the regulatory submission in the U.S. for approval of CASGEVY in children ages 5 to less than 12 years old with SCD or TDT. The FDA awarded Vertex a Commissioner’s National Priority Voucher for this pediatric submission, indicating an accelerated timeline for review once the submission is accepted. JOURNAVX (suzetrigine) for the treatment of moderate-to-severe acute pain

JOURNAVX is a first-in-class, oral, selective, non-opioid NaV1.8 pain signal inhibitor, approved in the U.S. for the treatment of moderate-to-severe acute pain.

Since the launch of JOURNAVX in March 2025, more than 1 million prescriptions have now been filled for JOURNAVX across the hospital and retail settings for a broad range of acute pain conditions. In the first quarter of 2026, more than 350,000 prescriptions were filled, and Vertex recorded revenue of $29 million. The Centers for Medicare and Medicaid Services (CMS) have approved the inclusion of JOURNAVX in the NOPAIN Act separate payment list, with a retroactive payment date of January 23, 2026. Addition to the NOPAIN list provides a separate payment for non-opioid medicines such as JOURNAVX in the hospital outpatient and ambulatory surgical center settings. Vertex has reached an agreement with a major pharmacy benefit manager for Medicare Part D coverage for JOURNAVX, effective May 1. The agreement adds approximately 10 million lives covered under Part D. Twenty-two states now provide coverage for JOURNAVX via Medicaid. In total, approximately 240 million individuals now have reimbursed access to JOURNAVX across a wide range of commercial and government payers. Select R&D Pipeline Programs

Cystic Fibrosis

Consistent with its commitment to serial innovation and bringing as many patients as possible to normal levels of CFTR function, Vertex is evaluating VX-828, the first of the next-generation 3.0 CFTR corrector class, in a proof-of-concept study in people with CF. Vertex is on track to complete dosing in this study in the first half of 2026 and share results in the second half. Vertex is enrolling and dosing first-in-human studies with VX-581 and VX-272, additional next-generation 3.0 CFTR correctors. Vertex has ended the Phase 1/2 study of VX-522 after observing persistent tolerability issues in the study. The early termination precludes assessment of efficacy and full safety and prevents further development of the VX-522 program. Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex continues to advance preclinical assets for gentler conditioning for CASGEVY, which could broaden the eligible patient population. Acute and Peripheral Neuropathic Pain (PNP)

Vertex is on track to complete enrollment in both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy (DPN), a form of peripheral neuropathic pain (PNP), by the end of 2026. Vertex also continues to enroll and dose people with DPN in a Phase 2 study of VX-993. Vertex continues to advance preclinical assets that inhibit NaV1.7 for use alone or in combination with a NaV1.8 inhibitor in acute and neuropathic pain. IgA Nephropathy (IgAN) and Other B Cell-Mediated Diseases

Vertex is developing povetacicept for multiple diseases. Povetacicept is a dual inhibitor of the BAFF and APRIL cytokines, which play key roles in the pathogenesis of multiple B cell-mediated autoimmune diseases. Povetacicept has pipeline-in-a-product potential and represents a potentially best-in-class approach to control B cell activity in IgAN, primary membranous nephropathy (pMN), and generalized myasthenia gravis (gMG).

In March, Vertex reported positive Week 36 interim analysis results for the primary and all secondary endpoints in the RAINIER Phase 3 trial of povetacicept in adults with IgAN. Based on these results, Vertex completed the submission of its rolling biologics license application (BLA) to the FDA in March for potential accelerated approval in the U.S. Vertex is using a Priority Review Voucher and therefore expects the FDA review of povetacicept’s BLA to be expedited to six months from the date of the FDA’s acceptance of the BLA. Vertex recently completed enrollment in the Phase 2 portion of the Phase 2/3 OLYMPUS pivotal study of povetacicept in people with pMN and initiated the Phase 3 portion. Enrollment and dosing in the trial are ongoing. The FDA has granted Fast Track and Orphan Drug designations for povetacicept in pMN, and the EMA has granted Priority Medicines (PRIME) designation. Vertex has initiated a placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG. APOL1-Mediated Kidney Disease (AMKD)

Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.

In the second half of 2025, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in people with primary AMKD and will conduct the pre-planned interim analysis for potential accelerated approval after this cohort reaches 48 weeks of treatment. Vertex expects to share data from the interim analysis in early 2027. The AMPLITUDE study is on track to complete full enrollment in the second half of 2026. Vertex has completed enrollment in the AMPLIFIED Phase 2 study of inaxaplin. AMPLIFIED is a study of people with AMKD with moderate proteinuria, and people with AMKD and Type 2 diabetes — populations not being studied in the AMPLITUDE trial. Vertex is on track to complete dosing and share data from the AMPLIFIED study in the second half of 2026. Type 1 Diabetes (T1D)

Vertex is evaluating stem cell-derived, fully differentiated islet cell therapies for patients suffering from T1D, with the goal of developing a potential one-time functional cure for this disease.

Vertex has completed the internal manufacturing analysis for the Phase 1/2/3 study of zimislecel in people with T1D and has resumed dosing in the study. Multiple patients have been treated since the resumption of dosing. The company expects to provide updated timelines for study completion later this year. Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Vertex is developing small molecule correctors that restore function to polycystin 1 (PC1) protein variants, with the goal of addressing the underlying cause of ADPKD.

Vertex is enrolling and dosing AGLOW, a Phase 2 study of VX-407 in patients with a subset of variants in the PKD1 gene, which encodes the PC1 protein, estimated to be up to approximately 30,000 (or up to approximately 10%) of the overall patient population living with ADPKD. AGLOW is a 24-patient, single-arm, 52-week, Phase 2 proof-of-concept study that will evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV). AGLOW is on track to complete enrollment in the second half of 2026. Myotonic Dystrophy Type 1 (DM1)

Vertex is evaluating multiple approaches that target the underlying cause of DM1. Vertex’s lead approach, VX-670, is an oligonucleotide linked to a cyclic peptide, which holds the potential to promote effective delivery into cells and address the causal biology of DM1.

Vertex continues to enroll and dose the MAD portion of the GALILEO global Phase 1/2 clinical trial of VX-670 in people with DM1; the study is assessing both safety and efficacy. Vertex is on track to complete enrollment and dosing in the trial and share results in the second half of 2026. Additional Earlier Stage R&D Programs

Consistent with its overall strategy, Vertex takes a serial innovation approach to all of its programs, with additional assets or approaches across its portfolio.

Non-GAAP Financial Measures

In this press release, Vertex's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, non-GAAP financial results and guidance exclude from Vertex's pre-tax income (i) stock-based compensation expense, (ii) intangible asset amortization expense, (iii) gains or losses related to the fair value of the company's strategic investments, (iv) increases or decreases in the fair value of contingent consideration, (v) an intangible asset impairment charge, and (vi) other adjustments. The company's non-GAAP financial results also exclude from its provision for income taxes the estimated tax impact related to its non-GAAP adjustments to pre-tax income described above and certain discrete items. These results should not be viewed as a substitute for the company’s GAAP results and are provided as a complement to results provided in accordance with GAAP. Management believes these non-GAAP financial measures help indicate underlying trends in the company's business, are important in comparing current results with prior period results and provide additional information regarding the company's financial position that the company believes is helpful to an understanding of its ongoing business. Management also uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally, to manage the company's business and to evaluate its performance. The company’s calculation of non-GAAP financial measures likely differs from the calculations used by other companies. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached financial information.

The company provides guidance regarding combined R&D, AIPR&D and SG&A expenses and effective tax rate on a non-GAAP basis. Unless otherwise noted, the guidance regarding combined R&D, AIPR&D and SG&A expenses does not include estimates associated with any potential future business development transactions, including collaborations, asset acquisitions and/or licensing of third-party intellectual property rights. The company does not provide guidance regarding its GAAP effective tax rate because it is unable to forecast with reasonable certainty the impact of excess tax benefits related to stock-based compensation and the possibility of certain discrete items, which could be material.

  Vertex Pharmaceuticals Incorporated

Consolidated Statements of Income

(unaudited, in millions, except per share amounts)

  Three Months Ended March 31,

2026

2025

Revenues:

Product revenues, net

$

2,986.9

$

2,760.2

Other revenues

—

10.0

Total revenues

2,986.9

2,770.2

Costs and expenses:

Cost of sales

392.8

363.0

Research and development expenses

961.6

979.7

Acquired in-process research and development expenses

0.5

19.8

Selling, general and administrative expenses

493.7

396.4

Intangible asset impairment charge

—

379.0

Change in fair value of contingent consideration

0.2

2.2

Total costs and expenses

1,848.8

2,140.1

Income from operations

1,138.1

630.1

Interest income, net

114.8

117.9

Other expense, net

—

(17.6

)

Income before provision for income taxes

1,252.9

730.4

Provision for income taxes

221.5

84.1

Net income

$

1,031.4

$

646.3

Net income per common share:

Basic

$

4.06

$

2.52

Diluted

$

4.02

$

2.49

Shares used in per share calculations:

Basic

254.1

256.9

Diluted

256.3

259.5

  Vertex Pharmaceuticals Incorporated

Total Revenues

(unaudited, in millions)

  Three Months Ended March 31,

2026

2025

TRIKAFTA/KAFTRIO

$

2,354.7

$

2,535.5

ALYFTREK

424.4

53.9

Other CF product revenues (1)

135.9

155.3

Total CF product revenues, net

2,915.0

2,744.7

CASGEVY

42.9

14.2

JOURNAVX

29.0

1.3

Product revenues, net

2,986.9

2,760.2

Other revenues

—

10.0

Total revenues

$

2,986.9

$

2,770.2

1: Includes KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI

  Vertex Pharmaceuticals Incorporated

Reconciliation of GAAP to Non-GAAP Financial Information

(unaudited, in millions, except percentages)

  Three Months Ended March 31,

2026

2025

GAAP cost of sales

$

392.8

$

363.0

Stock-based compensation expense

(3.2

)

(2.6

)

Intangible asset amortization expense

(5.0

)

(5.0

)

Non-GAAP cost of sales

$

384.6

$

355.4

GAAP research and development expenses

$

961.6

$

979.7

Stock-based compensation expense

(101.7

)

(100.1

)

Intangible asset amortization expense

(0.6

)

(0.6

)

Non-GAAP research and development expenses

$

859.3

$

879.0

Acquired in-process research and development expenses

$

0.5

$

19.8

GAAP selling, general and administrative expenses

$

493.7

$

396.4

Stock-based compensation expense

(61.5

)

(63.4

)

Non-GAAP selling, general and administrative expenses

$

432.2

$

333.0

Combined non-GAAP R&D, AIPR&D and SG&A expenses

$

1,292.0

$

1,231.8

GAAP other expense, net

$

—

$

(17.6

)

Decrease in fair value of strategic investments

2.0

15.0

Non-GAAP other income (expense), net

$

2.0

$

(2.6

)

GAAP provision for income taxes

$

221.5

$

84.1

Tax adjustments (2)

58.6

160.1

Non-GAAP provision for income taxes

$

280.1

$

244.2

GAAP effective tax rate

17.7

%

11.5

%

Non-GAAP effective tax rate

19.6

%

18.8

%

  Vertex Pharmaceuticals Incorporated

Reconciliation of GAAP to Non-GAAP Financial Information (continued)

(unaudited, in millions, except per share amounts)

  Three Months Ended March 31,

2026

2025

GAAP operating income

$

1,138.1

$

630.1

Stock-based compensation expense

166.4

166.1

Intangible asset impairment charge

—

379.0

Intangible asset amortization expense

5.6

5.6

Increase in fair value of contingent consideration

0.2

2.2

Non-GAAP operating income

$

1,310.3

$

1,183.0

GAAP net income

$

1,031.4

$

646.3

Stock-based compensation expense

166.4

166.1

Intangible asset impairment charge

—

379.0

Intangible asset amortization expense

5.6

5.6

Decrease in fair value of strategic investments

2.0

15.0

Increase in fair value of contingent consideration

0.2

2.2

Total non-GAAP adjustments to pre-tax income

174.2

567.9

Tax adjustments (2)

(58.6

)

(160.1

)

Non-GAAP net income

$

1,147.0

$

1,054.1

Net income per diluted common share:

GAAP

$

4.02

$

2.49

Non-GAAP

$

4.47

$

4.06

Shares used in diluted per share calculations:

GAAP and Non-GAAP

256.3

259.5

  2: In the three months ended March 31, 2026 and 2025, “Tax adjustments” included the estimated income taxes related to non-GAAP adjustments to the company's pre-tax income and excess tax benefits related to stock-based compensation.

  Vertex Pharmaceuticals Incorporated

Condensed Consolidated Balance Sheets

(unaudited, in millions)

  March 31, 2026

December 31, 2025

Assets

Cash, cash equivalents and marketable securities

$

7,246.7

$

6,608.1

Accounts receivable, net

1,996.1

2,052.8

Inventories

1,766.7

1,686.8

Prepaid expenses and other current assets

720.8

853.3

Total current assets

11,730.3

11,201.0

Property and equipment, net

1,608.4

1,520.3

Goodwill and other intangible assets, net

1,506.5

1,512.2

Deferred tax assets

2,947.8

2,897.9

Operating lease assets

1,685.1

1,562.7

Long-term marketable securities

5,749.9

5,712.3

Other long-term assets

1,256.4

1,236.6

Total assets

$

26,484.4

$

25,643.0

Liabilities and Shareholders' Equity

Accounts payable and accrued expenses

$

3,473.5

$

3,432.9

Other current liabilities

407.1

428.3

Total current liabilities

3,880.6

3,861.2

Long-term operating lease liabilities

1,986.5

1,846.5

Other long-term liabilities

1,255.4

1,269.5

Shareholders' equity

19,361.9

18,665.8

Total liabilities and shareholders' equity

$

26,484.4

$

25,643.0

Common shares outstanding

254.2

254.0

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America, and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit at www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Vertex and members of the Vertex senior management team. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements include, without limitation, Dr. Kewalramani's statements in this press release, the information provided regarding future financial performance and operations, the section captioned “Full Year 2026 Financial Guidance” and statements regarding (i) expectations for $500 million or more in non-CF product revenue and an immaterial cost impact from tariffs in 2026, (ii) expectations for continued growth in CF, including by increasing the number of CF patients taking its medicines through new approvals and reimbursement agreements, treatment of younger patients, increased survival, and expansion into additional geographies, (iii) beliefs regarding Vertex’s work to secure access to ALYFTREK in additional countries, (iv) beliefs regarding the anticipated benefits, eligible patient population, and access to CASGEVY, (v) expectations regarding the potential benefits and access to JOURNAVX, and anticipated benefits of being added to the NOPAIN list, (vi) expectations to submit for approval with global regulators for ALYFTREK in children ages two to five years in the first half of 2026, and to enroll and dose in the pivotal study of ALYFTREK in children ages one to less than two years, (vii) expectations to complete dosing in the clinical trial evaluating VX-828 in the first half of 2026, plans to share VX-828 data in the second half of 2026, and expectations for the VX-581 and VX-272 studies, (viii) expectations for CASGEVY, including expectations for potential accelerated timelines for review of the FDA submission, and advancing preclinical assets for gentler conditioning for CASGEVY, which could broaden the eligible patient population, (ix) expectations to complete enrollment in both Phase 3 studies of suzetrigine in DPN by the end of 2026, plans for the Phase 2 study of VX-993 in DPN, and plans for advancement of additional preclinical assets that inhibit NaV1.7, (x) expectations with respect to povetacicept, including beliefs about its potential benefits and therapeutic scope, its potential to be a best-in-class approach to control B cell activity in IgAN, pMN and gMG, and its potential to be a pipeline-in-a-product, expectations regarding povetacicept in IgAN, including the anticipated expedited review of the BLA, and expectations for povetacicept in pMN, including with respect to enrollment and dosing in the study, (xi) expectations regarding the AMPLITUDE Phase 2/3 trial of inaxaplin in AMKD, including expectations regarding the interim analysis, plans to share data in early 2027, and expectations to complete full enrollment in the second half of 2026, and expectations to complete dosing in the AMPLIFIED Phase 2 study of inaxaplin and share data in the second half of 2026, (xii) expectations regarding the clinical benefits and goals for zimislecel in T1D, and expectations to provide updated timelines for study completion in 2026, (xiii) expectations regarding the ADPKD program and the Phase 2 study evaluating VX-407, including expectation to complete enrollment in the AGLOW study in the second half of 2026, (xiv) beliefs regarding the potential benefits and clinical status of VX-670 for the treatment in people with DM1 and expectations to complete enrollment and dosing in the trial and share results in the second half of 2026, and (xv) the company’s beliefs with respect to additional assets or approaches across its portfolio. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the company's expectations regarding its 2026 full year revenues, expenses, and effective tax rates and that impact from tariffs in 2026 may be incorrect (including because one or more of the company's assumptions underlying its expectations may not be realized), that we may be unable to further successfully commercialize ALYFTREK as a treatment for CF, JOURNAVX as a treatment for acute pain, and CASGEVY as a treatment for SCD and TDT, that external factors may have different or more significant impacts on the company's business or operations than the company currently expects, that data from preclinical testing or clinical trials, especially if based on a limited number of patients, may not be indicative of final results or available on anticipated timelines, that patient enrollment in the company’s trials may be delayed, that the company may not realize the anticipated benefits from collaborations with third parties, that data from the company's development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, that regulatory submissions or approvals may not occur on the anticipated timeline, or at all, that interactions with regulators may cause delays in the company’s pipeline programs, and that anticipated commercial launches may be delayed, if they occur at all. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Vertex’s business, particularly those risks listed under the heading “Risk Factors” and the other cautionary factors discussed in Vertex’s periodic reports filed with the SEC, including Vertex’s annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, all of which are filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC’s website at www.sec.gov. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

Conference Call and Webcast

The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2026 Earnings Call.”

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

(VRTX-E)

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.

Vertex reported first-quarter revenue of $2.99 billion, missing analyst estimates of $3.03 billion, according to Benzinga Pro. The company posted first-quarter adjusted earnings of $4.47 per share, beating estimates of $4.31 per share.

"CASGEVY and JOURNAVX delivered more than 25 percent of our growth this quarter, underscoring the strength of the increasingly diversified revenue base. As we execute across the commercial portfolio and pipeline and build our fourth franchise in nephrology, Vertex is poised to continue to deliver for patients and create long-term value," said Reshma Kewalramani, president and CEO of Vertex.

Vertex affirmed its full-year revenue guidance of $12.95 billion to $13.10 billion versus estimates of $13.06 billion.

Vertex shares fell 2.7% to trade at $418.83 on Tuesday.

These analysts made changes to their price targets on Vertex following earnings announcement.

RBC Capital analyst Brian Abrahams maintained the stock with an Outperform rating and raised the price target from $541 to $543. Bernstein analyst William Pickering maintained the stock with an Outperform rating and lowered the price target from $577 to $572. Considering buying VRTX stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.

Vertex (VERX - Free Report) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.13%. A quarter ago, it was expected that this company would post earnings of $0.17 per share when it actually produced earnings of $0.17, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Vertex, which belongs to the Zacks Internet - Software industry, posted revenues of $196.65 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.04%. This compares to year-ago revenues of $177.06 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Vertex shares have lost about 36.6% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for Vertex?While Vertex has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Vertex was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.17 on $203.13 million in revenues for the coming quarter and $0.73 on $826.8 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Ceva (CEVA - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.

This chip designer is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -66.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Ceva's revenues are expected to be $26.23 million, up 8.2% from the year-ago quarter.

Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript

2 hours ago

CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat

CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:KO

Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares

2 hours ago

Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,054 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $60.37, for a total transaction of $15,759,829.98. Following the completion of the sale, the insider owned 2,671,855 shares in the company, valued at $161,299,886.35. This represents a 8.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

NYSE:BROS

Read Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in Stock

2 hours ago

Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,055 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $63.02, for a total value of $16,451,686.10. Following the completion of the transaction, the insider owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

NYSE:BROS

Read Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of Stock

2 hours ago

Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 749,999 shares of Dutch Bros stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $60.39, for a total transaction of $45,292,439.61. Following the completion of the sale, the chairman owned 2,671,855 shares of the company's stock, valued at $161,353,323.45. This represents a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:BROS

Read Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) Stock

2 hours ago

Insider Selling: Dutch Bros (NYSE:BROS) Chairman Sells 750,000 Shares of StockMarketBeat

Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 750,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $63.02, for a total value of $47,265,000.00. Following the sale, the chairman owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:BROS

Read Insider Selling: Dutch Bros (NYSE:BROS) Chairman Sells 750,000 Shares of Stock

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

June 01, 2026 08:00 ET  | Source: Vertex Inc.

KING OF PRUSSIA, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will present at the 46th Annual William Blair Growth Stock Conference on Wednesday, June 3, 2026 at 2:40 PM Central Time.

A live webcast and replay of the presentation will be available on Vertex’s investor relations website at ir.vertex.com.

About Vertex

Vertex, Inc. is a leading provider of tax and compliance technology for global commerce, combining deep domain expertise with advanced technologies and responsible AI to help businesses transact, comply, and grow with confidence. Powered by AI-driven tax automation, Vertex enables global enterprises to manage complex tax workflows with greater speed, accuracy, and agility. Headquartered in North America, and with offices in South America and Europe, Vertex empowers the world’s leading brands to simplify the complexity of continuous compliance.

For more information, visit www.vertexinc.com or follow us on X and LinkedIn; or subscribe on YouTube.

Investor Relations contact:
Joe Crivelli
Vertex, Inc.
[email protected]